Form 10-Q - Quarterly report [Sections 13 or 15(d)]

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended October 31, 2024

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from         to

 

Commission File No. 001-40101

 

BRIACELL THERAPEUTICS CORP.

(Exact name of registrant as specified in its charter)

 

British Columbia, Canada		47-1099599
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

 

235 15th Street, Suite 300, West Vancouver, BC, V7T 2X1

(Address of Principal Executive Offices, including zip code)

604-921-1810

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading Symbol		Name of each exchange on which registered
Common shares, no par value		BCTX		The Nasdaq Stock Market LLC
Warrants to purchase common shares, no par value		BCTXW		The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

	☐ Large accelerated filer	☐Accelerated filer
	☒ Non-accelerated filer	☒ Smaller reporting company
		☒ Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes ☒ No ☐

 

As of December 16, 2024, 44,204,161 common shares, no par value per share, of the Company were issued and outstanding.

 

 

 

 

 

BRIACELL THERAPEUTICS CORP.

Form 10-Q

Table of Contents

 

		Page
Part I. Financial Information		3
Item 1.	Financial Statements	3
	Condensed Consolidated Balance Sheets as of October 31, 2024 (unaudited) and July 31, 2024 (audited)	3
	Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended October 31, 2024	4
	Unaudited Condensed Consolidated Statements of Changes in Shareholders’ Equity (Deficit) for the three months ended October 31, 2024	5
	Unaudited Condensed Consolidated Statement of Cash Flows for the three months ended October 31, 2024	6
	Notes to Unaudited Condensed Consolidated Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	18
Item 3.	Quantitative and Qualitative Disclosures Regarding Market Risk	22
Item 4.	Controls and Procedures	23
Part II. Other Information		23
Item 1.	Legal Proceedings	23
Item 1A.	Risk Factors	23
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	23
Item 3.	Defaults Upon Senior Securities	23
Item 4.	Mine Safety Disclosures	23
Item 5.	Other Information	24
Item 6.	Exhibits	24
Part III. Signatures		25

 

2

 

 

PART I-FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

BRIACELL THERAPEUTICS CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS

 

		October 31, 2024				July 31, 2024
		(Unaudited)				(Audited)
ASSETS
CURRENT ASSETS:
Cash and cash equivalents		$	5,792,265			$	862,089
Amounts receivable and prepaid expenses			2,426,830				2,791,765
Total current assets			8,219,095				3,653,854
NON-CURRENT ASSETS:
Equity Investment in BC Therapeutics			421,975				418,490
Intangible assets, net			195,978				199,796
Property and equipment, net			365,336				388,175
Long term prepaid expenses			1,211,946				1,211,946
Total non-current assets			2,195,235				2,218,407
Total assets		$	10,414,330			$	5,872,261
LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES:
Trade payables		$	4,233,968			$	7,170,781
Accrued expenses and other payables			754,668				290,376
Total current liabilities			4,988,636				7,461,157
NON-CURRENT LIABILITIES:
Warrant liability			1,712,679				1,096,036
Total non-current liabilities			1,712,679				1,096,036
SHAREHOLDERS’ EQUITY (DEFICIT):
Share capital of no par value - Authorized: unlimited at October 31, 2024 and July 31, 2024, Issued and outstanding: 36,183,161 shares October 31, 2024 and 18,284,661 July 31, 2024, respectively			82,040,741				72,166,414
Share-based payment reserved			9,456,232				9,189,261
Warrant reserve			3,930,221				1,844,296
Accumulated other comprehensive loss			(138,684	)			(138,684	)
Non-controlling interest			(329,623	)			(302,522	)
Accumulated deficit			(91,245,872	)			(85,443,697	)
Total shareholders’ equity (deficit)			3,713,015				(2,684,932	)
Total liabilities and shareholders’ equity		$	10,414,330			$	5,872,261

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

3

 

 

BRIACELL THERAPEUTICS CORP.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

 

		Three months ended
		October 31,
		2024				2023
Operating expenses:
Research and development expenses		$	3,665,341				6,857,257
General and administrative expenses			1,487,491				1,645,771
Total operating expenses			5,152,832				8,503,028
Operating loss			(5,152,832	)			(8,503,028	)
Financial income, net			11,714				179,822
Change in fair value of the warrant liability			(616,643	)			14,282,078
Share of loss on equity investment			(71,515	)			-
Net income (loss) for the period		$	(5,829,276	)		$	5,958,872
Net loss attributable to non-controlling interest			(27,101	)			(42,671	)
Net income (loss) for the period attributable to BriaCell			(5,802,175	)			6,001,543
Net income (loss) per share attributable to BriaCell – basic		$	(0.22	)		$	0.38
Net income (loss) per share attributable to BriaCell – diluted			(0.22	)			(0.50	)
Weighted average number of shares used in computing net basic earnings per share of common stock			26,641,036				15,981,726
Weighted average number of shares used in computing net diluted earnings per share of common stock			26,641,036				16,674,891

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

4

 

 

BRIACELL THERAPEUTICS CORP.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

(Unaudited)

FOR THE THREE MONTHS ENDED OCTOBER 31, 2024

 

		Share capital								Additional paid in				Accumulated other comprehensive				Accumulated				Non- controlling				Total shareholders’ equity
		Number				Amount				capital				loss				Equity				interest				(deficit)
Balance, July 31, 2023			15,981,726			$	69,591,784			$	7,421,950			$	(138,684	)		$	(80,652,231	)			-			$	(3,777,181	)
Instruments issued to minority shareholders at the Arrangement Date			-				-				(36,767	)			-				-				(162,440	)			(199,207	)
Issuance of options			-				-				533,816				-				-				-				533,816
Income (loss) for the period			-				-				-				-				6,001,543				(42,671	)			5,958,872
Balance, October 31, 2023			15,981,726			$	69,591,784			$	7,918,999			$	(138,684	)		$	(74,650,688	)			(205,111	)		$	2,516,300

 

		Share capital								Additional paid in				Warrant				Accumulated other comprehensive				Accumulated				Non- Controlling				Total shareholders’ equity
		Number				Amount				capital				reserve				loss				deficit				Interest				(deficit)
Balance, July 31, 2024			18,284,661			$	72,166,414			$	9,189,261			$	1,844,296			$	(138,684	)		$	(85,443,697	)		$	(302,522	)		$	(2,684,932	)
Issuance of Options			-				-				266,971				-				-				-				-				266,971
Exercise of prefunded warrants			100,000				-				-				-				-				-				-				-
Exercise of broker warrants			345,000				442,677				-				(149,426	)			-				-				-				293,251
Issuance of units			17,453,500				9,431,650				-				2,235,351				-				-				-				11,667,001
Net loss for the period			-				-				-				-				-				(5,802,175	)			(27,101	)			(5,829,276	)
Balance, October 31, 2024			36,183,161			$	82,040,741			$	9,456,232			$	3,930,221			$	(138,684	)		$	(91,245,872	)		$	(329,623	)		$	3,713,015

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

5

 

 

BRIACELL THERAPEUTICS CORP.

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(Unaudited)

 

		Three months ended October 31,
		2024				2023
Cash flow from operating activities
Net income (loss) for the period		$	(5,829,276	)		$	5,958,872
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization			3,818				3,818
Depreciation			22,839				-
Share-based compensation			266,971				533,816
Equity losses			71,515				-
Change in fair value of warrants			616,643				(14,282,078	)
Changes in assets and liabilities:
Decrease (increase) in amounts receivable			736,788				(2,537	)
(Increase) decrease in prepaid expenses			(371,853	)			937,816
Decrease in accounts payable			(2,936,813	)			(689,824	)
Increase (decrease) in accrued expenses and other payables			464,292				(65,128	)
Total cash flow from operating activities			(6,955,076	)			(7,605,245	)
Cash flows from Investing activities
Equity investment in BC Therapeutics			(75,000	)			-
Total cash flow from investing activities			(75,000	)			-
Cash flows from financing activities
Proceeds from exercise of warrants			293,251				-
Proceeds from the issuance of shares, net of issuance costs			11,667,001				-
Total cash flow from financing activities			11,960,252				-
Increase (decrease) in cash and cash equivalents			4,930,176				(7,605,245	)
Cash and cash equivalents at beginning of the period			862,089				21,251,092
Cash and cash equivalents at end of the period		$	5,792,265			$	13,645,847

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

6

 

 

BriaCell Therapeutics Corp

Notes to the Condensed Consolidated Financial Statements

(Unaudited, expressed in US Dollars, except share and per share data and unless otherwise indicated)

 

NOTE 1: GENERAL AND GOING CONCERN

 

	a.	BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) was incorporated under the Business Corporations Act (British Columbia) on July 26, 2006 and is listed on the Toronto Stock Exchange (“TSX”) under the symbol “BCT”. The Company also trades on the Nasdaq Capital Market (“NASDAQ”) under the symbols “BCTX” and “BCTXW”.
	b.	BriaCell is an immuno-oncology biotechnology company. The Company is currently advancing its Bria-IMT targeted immunotherapy program against end-stage breast cancer to Phase 3 study which has been approved by the FDA. BriaCell is also developing a personalized off-the-shelf immunotherapy, Bria-OTS™, and a soluble CD80 protein therapeutic which acts both as a stimulator of the immune system as well as an immune checkpoint inhibitor.
	c.	Basis of presentation of the financial statements:
		The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X promulgated by the U.S Securities and Exchange Commission (the “SEC”). Certain information or footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments consisting of a normal recurring nature which are necessary for a fair presentation of the financial position, operating results, and cash flows for the periods presented.
		The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report for the year ended July 31, 2024, filed with the SEC on October 28, 2024. The interim period results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year.

 

	d.	Going concern   The Company continues to devote substantially all of its efforts toward research and development activities. In the course of such activities, the Company has sustained operating losses and expects such losses to continue in the foreseeable future. The Company’s accumulated deficit as of October 31, 2024 was $91,245,872 and negative cash flows from operating activities during the three-month period ended October 31, 2024 was $6,955,076. The Company is planning to finance its operations by exploring additional sources of capital and financing, while managing its existing working capital resources. The Company’s ability to continue as a going concern is dependent upon its ability to attain future profitable operations and to obtain the necessary financing to meet its obligations arising from normal business operations when they come due. The uncertainty of the Company’s ability to raise such financial capital casts substantial doubt on the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company not be able to continue as a going concern. See note 5(b) for details of an $8.5 million gross and $5.0 million gross offering that was completed in September 2024 and October 2024, respectively.
	e.	The Company has two wholly-owned U.S. subsidiaries: (i) BriaCell Therapeutics Corp. (“BTC”), which was incorporated in April 3, 2014, under the laws of the state of Delaware, and (ii) BTC has a wholly-owned subsidiary, Sapientia Pharmaceuticals, Inc. (“Sapientia”), which was incorporated in September 20, 2012, under the laws of the state of Delaware. The Company also has one Canadian subsidiary: BriaPro Therapeutics Corp, (“BriaPro”) which was incorporated on May 15, 2023, under the Business Corporations Act (British Columbia). See also note 1f. (Sapientia and BTC and BriaPro together, the “Subsidiaries”).
	f.	On August 31, 2023, the Company closed a plan of arrangement spinout transaction (the “Arrangement”) pursuant to which certain pipeline assets of the Company, including Bria-TILsRx™ and protein kinase C delta (PKCδ) inhibitors for multiple indications including cancer (the “BriaPro Assets”), were spun-out to BriaPro Therapeutics Corp. (“BriaPro”), resulting in a 2/3rd owned subsidiary of the Company with the remaining 1/3rd held by BriaCell shareholders (“BriaCell Shareholders”).
		Pursuant to the terms of the Arrangement, BriaPro has acquired the entire right and interest in and to the BriaPro Assets in consideration for the issuance by BriaPro to the Company of BriaPro common shares. Under the terms of the Arrangement, for each BriaCell share held immediately prior to closing, BriaCell Shareholders receive one (1) common share of BriaPro, and one (1) new common share of BriaCell (retiring their old share) having the same terms and characteristics as the existing BriaCell common shares. The Company will remain listed on the NASDAQ Stock Market and Toronto Stock Exchange, and BriaPro is an unlisted reporting issuer in Canada.   Immediately following the closing of the Arrangement, the Company controls 2/3rd of the BriaPro common shares representing approximately 66.6% of the issued and outstanding common shares of BriaPro.   As a result of the Arrangement, there are 47,945,178 BriaPro common shares issued and outstanding. The Company now beneficially owns or controls approximately 31,963,452 BriaPro common shares, representing 2/3rd of the issued and outstanding BriaPro common shares.   Pursuant to the Arrangement, each BriaCell warrant in issuance at the time of the Arrangement shall, in accordance with its terms, entitle the holder thereof to receive, upon the exercise thereof, one BriaCell Share and one BriaPro Share for the original exercise price. Warrants issued by the Company, subsequent to the Arrangement are not subject to the terms above.   Upon the exercise of BriaCell Warrants, BriaCell shall, as agent for BriaPro, collect and pay to BriaPro an amount for each one (1) BriaPro Share so issued that is equal to the exercise price under the BriaCell Warrant multiplied by the fair market value of one (1) BriaPro Share at the Effective Date divided by the total fair market value of one (1) BriaCell Share and one (1) BriaPro Share at the Effective Date (“BriaPro Warrant Shares”).   Pursuant to the Arrangement, all Briacell option holders received the same amount of BriaPro options (“BriaPro Option”) and under the BriaPro incentive plan. The exercise price of the BriaCell options was apportioned between the BriaCell options and the BriaPro options, as follows:   Each one (1) BriaPro Option to acquire one (1) Share shall have an exercise price equal to the product obtained by multiplying the original exercise price of the BriaCell Option by the quotient obtained by dividing (A) the fair market value of a BriaPro Share at the Effective Date by (B) the aggregate fair market value of a BriaCell Share and a BriaPro Share at the Effective Date.   Pursuant to the Arrangement, all BriaCell Restricted Shares Units (“RSU”) holders received the same amount of BriaPro RSU’s under the BriaPro incentive plan.   Transition Services Agreement   On August 31, 2023, the Company and BriaPro executed a transition services agreement (the “Agreement”), pursuant to which BriaCell will provide certain research and development and head office services (the “Services”) to BriaPro for a fixed monthly fee of $20,000.   Briacell and BriaPro acknowledged the transitional nature of the Services and accordingly, as promptly as practicable, BriaPro agreed to use commercially reasonable efforts to transition each Service to its own internal organization or to obtain alternate third party providers to provide the Services.   In accordance with US GAAP’s Accounting Standards Codification 505 “Equity”, the Arrangement was determined to be a spinoff of nonmonetary assets which did not constitute a business. However, since the assets were transferred to an entity under the Company’s control, the assets is being recorded on the Company’s basis (carry value) and not at fair market value.

 

7

 

 

BriaCell Therapeutics Corp

Notes to the Condensed Consolidated Financial Statements

(Unaudited, expressed in US Dollars, except share and per share data and unless otherwise indicated)

 

NOTE 2: SIGNIFICANT ACCOUNTING POLICIES

 

a. Use of estimates:

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company’s management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities at the dates of the condensed consolidated financial statements, and the reported amount of expenses during the reporting periods. Actual results could differ from those estimates.

 

b. Prepaid expenses

 

The Company has prepaid certain expenses in respect of its pivotal phase III trial and estimates the period over which such expenses will be incurred. As of July 31, 2024, the Company revised its estimate of the time to completion in respect of this trial. Amounts estimated to be expenses in more than 12 months have been classified to long-term prepaid expenses.

 

c. The useful life of property and equipment

 

Property and equipment are depreciated over their useful lives. Useful lives are based on management’s estimates of the period that the assets will be used which are periodically reviewed for continued appropriateness. Changes to estimates can result in significant variations in the amounts charged to the consolidated statement of operations and comprehensive loss in specific periods.

 

d. Investment equity method:

 

Investments in entities over which the Company does not have a controlling financial interest but has significant influence are accounted for using the equity method, with the Company’s share of losses reported in the loss from equity method investments on the statements of operation and comprehensive loss. The Company has a 54.6% interest in BC Therapeutics. Management evaluates whether it has control over the investee in accordance with the guidance of ASC 810, which requires judgment to assess factors such as power over significant activities of the investee, exposure to variable returns, and the ability to affect those returns. Based on this evaluation, management determines whether control or significant influence is present for accounting purposes.

 

e. Recently issued and adopted accounting standards:

 

		As an “emerging growth company,” the Jumpstart Our Business Startups Act (“JOBS Act”) allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this extended transition period under the JOBS Act. The adoption dates discussed below reflect this election. The pronouncements below relate to standards that impact the Company.
	1.	In December 2023, the FASB issued ASU 2023-09 - Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This standard modifies the rules on income tax disclosures to require entities to disclose specific categories in the rate reconciliation, the income or loss from continuing operations before income tax expense or benefit, and income tax expense or benefit from continuing operations. ASU 2023-09 also requires entities to disclose their income tax payments to international, federal, state, and local jurisdictions. The ASU is effective for years beginning after December 15, 2024, but early adoption is permitted. This ASU should be applied on a prospective basis, although retrospective application is permitted. The Company is currently evaluating the impact of this standard on its financial statements and disclosures.
	2.	In March 2024, the FASB issued ASU 2024-01 - Compensation—Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar Awards. This standard clarifies whether profits interest and similar awards fall within the scope of stock-based compensation guidance as defined in ASC Topic 718, introducing examples to demonstrate this. The ASU includes scenarios where profits interest awards are classified as equity instruments or liability awards and situations where they fall outside ASC Topic 718, being accounted for under ASC Topic 710. The ASU is effective for years beginning after December 15, 2024, but early adoption is permitted. This ASU should be applied on a prospective basis, although retrospective application is permitted. The Company is currently evaluating the impact of this standard on its financial statements and disclosures.

 

8

 

 

BriaCell Therapeutics Corp

Notes to the Condensed Consolidated Financial Statements

(Unaudited, expressed in US Dollars, except share and per share data and unless otherwise indicated)

 

NOTE 3: INVESTMENT IN BC THERAPEUTICS INC.

 

		On December 21, 2021, the Company and BC Therapeutics, Inc. (“BC Therapeutics” or “the Investee”) entered a share purchase agreement (“SPA”), pursuant to which the Company initially provided a loan of $300,000 to BC Therapeutics, with no interest to be paid. Subsequently, in accordance with the SPA, this loan was converted into an equity investment in BC Therapeutics at a rate of $1.25 per share, resulting in a 37.5% ownership interest (“Initial Investment”).
		Pursuant to the SPA (“Initial Investment”), Briacell also received two options to invest an additional $225,000 per option at $1.25 per BC Therapeutics share. The first option expired on February 15, 2024 (“First BC Therapeutics Option”) and the second option expired on June 30, 2024 (“Second BC Therapeutics Options”, together, the “BC Therapeutic Options”). In accordance with ASC 321 and ASC 815, the BC Therapeutics Options were valued at $76,350 in accordance with the Black Scholes Option Price Model, using the following assumptions: Share price: $1.25, Exercise price: $1.25, Dividend yield: 0%, Risk free interest rate: 4.902%, Volatility: 100%.
		BC Therapeutics has a board of four representatives, with two representatives appointed by BriaCell and two representatives appointed by the existing shareholders. All significant decisions related to BC Therapeutics require the approval of at least a majority of the board members.
		The Company initially acquired a significant interest in BC Therapeutics on February 1, 2024, by exercising the First BC Therapeutics Option, increasing its ownership to 51.2%. On August 7, 2024, following the expiration of the original Second BC Therapeutics Option, the Company and BC Therapeutics amended the SPA to introduce new options, allowing the exercise in tranches of at least 20,000 shares at $1.25 per share. During the quarter ended October 31, 2024, the Company exercised this option in three tranches, totaling $75,000 for 60,000 shares. As of October 31, 2024, the Company holds 480,000 shares in BC Therapeutics, representing 54.6% of the total issued and outstanding shares.
		In accordance with ASC 810, the Company continues to account for the investment under the equity method of accounting as the Company does not exercise control over BC Therapeutics.

 

Changes in the Company’s equity investment in BC Therapeutics is summarized as follows:

 

Balance – August 1, 2023		$	-
Funding (including the value of the BC Therapeutics Options)			525,000
Share of losses			(106,510	)
Balance – July 31, 2024			418,490
Funding			75,000
Share of losses			(71,515	)
Balance – October 31, 2024		$	421,975

 

The following amounts represent the Company’s 54.6% share of the assets of BC Therapeutics:

  

		As of October 31, 2024
Current assets: Cash		$	2,805
Net assets		$	2,805

 

9

 

 

BriaCell Therapeutics Corp

Notes to the Condensed Consolidated Financial Statements

(Unaudited, expressed in US Dollars, except share and per share data and unless otherwise indicated)

 

NOTE 4: CONTINGENT LIABILITIES AND COMMITMENTS

 

	a.	BriaPro Warrants
		Upon the exercise of BriaCell Warrants, BriaCell shall, as agent for BriaPro, collect and pay to BriaPro an amount based on an agreed formula (detailed in note 1(f)). As of October 31, 2024, this amount totaled up to $241,164 and is eliminated on consolidation.
	b.	Lease
		The Company was previously in a 12-month commitment for office and lab space in Philadelphia, PA, costing approximately $38,110 per month. The lease expired on August 31, 2024, and as of October 2024, the Company continues to occupy the space on a month-to-month basis under the same terms.

 

NOTE 5: FAIR VALUE MEASUREMENTS

 

The following table presents information about our financial instruments that are measured at fair value on a recurring basis as of October 31, 2024 and July 31, 2024:

 

		Fair Value Measurements at
		October 31, 2024												July 31, 2024
		Level 1				Level 2				Total				Level 1				Level 2				Total
Financial Assets:
Cash and cash equivalents			5,792,265				-				5,792,265				862,089				-				862,089
Total assets measured at fair value		$	5,792,265			$	-			$	5,792,265			$	862,809			$	-			$	862,089
Financial liabilities:
Warrants liability			1,207,621				505,058				1,712,679				760,657				335,379				1,096,036
Total liabilities measured at fair value		$	1,207,621			$	505,058			$	1,712,679			$	760,657			$	335,379			$	1,096,036

 

We classify our cash and cash equivalents and the liability in respect of publicly traded warrants within Level 1 because we use quoted market prices in active markets.

 

The fair value of the warrant liability for non-public warrants is measured using inputs other than quoted prices included in Level 1 that are observable for the liability either directly or indirectly, and thus are classified as Level 2 financial instruments.

 

10

 

 

BriaCell Therapeutics Corp

Notes to the Condensed Consolidated Financial Statements

(Unaudited, expressed in US Dollars, except share and per share data and unless otherwise indicated)

 

NOTE 6: SHAREHOLDERS’ EQUITY

 

a. Authorized share capital

 

The authorized share capital consists of an unlimited number of common shares with no par value.

b. Issued share capital

 

(i)

The Company issued the following shares during the three-month period ended October 31, 2024:

 

	1.	On September 12, 2024, the Company completed a registered direct offering for the purchase and sale of 12,325,000 common shares of the Company at an offering price of $0.69 per share, for aggregate gross proceeds of approximately $8.5 million before deducting placement agent fees and other offering expenses (the “September 2024 Offering”).
		In connection with the September 2024 Offering, the Company issued 616,250 placement agent warrants with an exercise price of $0.8625 per share. These placement agent warrants are exercisable beginning on March 11, 2025, and expire five years from the date of issuance. The fair value of the broker warrants was determined to be $247,800 using the Black-Scholes option pricing model, with the following assumptions: share price - $0.63; exercise price - $0.8625; expected life – 5 years; annualized volatility - 109%; dividend yield - 0%; risk-free rate – 3.469%, non-marketability discount – 16.38%.
		The amount was credited to the warrant reserve at the date of the September 2024 Offering.

 

2. On October 2, 2024, the Company closed a registered direct offering for the purchase and sale of 5,128,500 common shares of the Company and warrants to purchase up to an aggregate of 5,128,500 common shares of the Company for aggregate gross proceeds of $5 million before deducting placement agent fees and other offering expenses (the “October 2024 Offering”). Each common share was sold together with one warrant to purchase one common share at a combined purchase price of $0.975. The warrants have an exercise price of $0.85 per share, are immediately exercisable, and expire five years from the date of issuance (“October 2024 Warrants”).

 

In connection with the October 2024 Offering, the Company issued 256,425 placement agent warrants. The placement agent warrants are immediately exercisable at an exercise price of $1.21875 per share and expire five years from the date of issuance.

 

The fair value of the 5,128,500 October 2024 Warrants was determined to be $2,211,266 using the Black-Scholes option pricing model, with the following assumptions: share price - $0.54; exercise price - $0.85; expected life – 5 years; annualized volatility - 121%; dividend yield - 0%; risk-free rate – 3.553%.

 

The fair value of the 256,425 placement agent warrants was determined to be $204,128 using the Black-Scholes option pricing model, with the following assumptions: share price - $1.01; exercise price - $1.22; expected life – 5 years; annualized volatility - 112%; dividend yield - 0%; risk-free rate – 3.561%.

 

The amounts were credited to the warrant reserve at the date of the October 2024 Offering.

 

During October 2024, 345,000 October 2024 Warrants with an exercise price of $0.85 were exercised for gross proceeds of $293,250. The Company issued 345,000 common shares in respect of the exercise of these warrants.

 

11

 

 

c. Share Purchase Warrants

 

A summary of changes in share purchase warrants for the three-month period ending October 31, 2024 is presented below:

 

		Number of options outstanding				Weighted average exercise price (*)
Balance, July 31, 2024			10,524,585			$	4.92
Exercised			(345,000	)			(0.85	)
Granted in the October 2024 Offering			5,128,500				0.85
Balance, October 31, 2024			15,308,085			$	3.65

 

(ii)

As of October 31, 2024, warrants outstanding were as follows:

 

Number of Warrants				Exercise Price(*)				Exercisable At October 31, 2024				Expiry Date
	51,698			$	3.89				51,698			November 16, 2025
	3,896,809			$	5.31				3,896,809			February 26, 2026 – April 26, 2026
	4,173,143			$	6.19				4,173,143			December 7, 2026
	2,402,935			$	2.11				(*)-			November 17, 2029
	4,783,500			$	0.85				4,783,500			October 2, 2029
	15,308,085								12,898,150

 

(*)

Exercisable from November 17, 2024.

 

d. Compensation Warrants

 

(i)

A summary of changes in compensation warrants for the three-month period ended October 31, 2024 is presented below:

 

		Number of warrants outstanding				Weighted average exercise price (*)
Balance, July 31, 2024			96,652				3.92
Granted in the September 2024 Offering			616,250				0.86
Granted in the October 2024 Offering			256,425				1.22
Balance, October 31, 2024			969,327			$	1.26

 

(ii)

As of October 31, 2024, compensation warrants outstanding were as follows:

 

Number of Warrants				Exercise Price				Exercisable At October 31, 2024				Expiry Date
	4,890			$	3.89				4,890			November 16, 2025
	17,074			$	5.31				17,074			February 26, 2026
	24,688			$	6.19				24,688			June 7, 2026
	50,000			$	2.32				(*)-			May 17, 2029
	616,250			$	0.86				(**)-			March 13, 2030
	256,425			$	1.22				256,425			October 2, 2029
	969,327								303,077

 

(*)

Exercisable from November 17, 2024.

(**)

Exercisable from March 11, 2025.

 

12

 

 

BriaCell Therapeutics Corp

Notes to the Condensed Consolidated Financial Statements

(Unaudited, expressed in US Dollars, except share and per share data and unless otherwise indicated)

 

NOTE 6: SHAREHOLDERS’ EQUITY (Cont.)

 

e. Warrant liability continuity

 

The following table presents the summary of the changes in the fair value of the warrants:

 

		Warrants liability
Balance as of August 1, 2024		$	1,096,036
Change in fair value during the period		$	616,643
Balance as of October 31, 2024		$	1,712,679

 

The key inputs used in the valuation of the non-public warrants as of October 31, 2024 and at July 31, 2024 were as follows:

 

		October 31, 2024				July 31, 2024
Share price		$	0.81			$	0.75
Exercise price		$	5.31-6.19			$	5.31-6.19
Expected life (years)			1.32-2.10				1.57-2.35
Volatility			93-106	%			77-79	%
Dividend yield			0	%			0	%
Risk free rate			4.19-4.29	%			4.27	%

 

The key inputs used in the valuation of the of the BriaPro Warrant Shares as of October 31, 2024 were as follows:

 

		August 31, 2023 (Effective Date)				October 31, 2024
Share price		$	0.0365			$	0.0365
Exercise price		$	0.0206-0.0308			$	0.0206-0.0308
Expected life (years)			2.21-3.27				1.05-2.10
Volatility			100	%			93-106	%
Dividend yield			0	%			0	%
Risk free rate			4.40	%			3.07	%

 

13

 

 

NOTE 7: SHARE-BASED COMPENSATION

 

	a.	On August 2, 2022, the Company approved an omnibus equity incentive plan (“Omnibus Plan), which will permit the Company to grant incentive stock options, preferred share units, restricted share units (“RSU’s”), and deferred share units (collectively, the “Awards”) for the benefit of any employee, officer, director, or consultant of the Company or any subsidiary of the Company. The maximum number of shares available for issuance under the Omnibus Plan shall not exceed 15% of the issued and outstanding Shares, from time to time, less the number of Shares reserved for issuance under all other security-based compensation arrangements of the Company, including the existing Stock Option Plan. On February 9, 2023, the Omnibus Plan was approved by the shareholders.
	b.	The following table summarizes the number of options granted to directors, officers, employees and consultants under the option plan for three-month period ended October 31, 2024 and related information:

 

		Number of options				Weighted average exercise price				Weighted average remaining contractual term (in years)				Aggregate intrinsic value
Balance as of July 31, 2024			2,131,400			$	6.16				2.52			$	-
Balance as of October 31, 2024			2,131,400				6.15				2.27				-
Exercisable as of October 31, 2024			2,018,775			$	6.16				2.20			$	-

 

As of October 31, 2024, there are $519,598 of total unrecognized costs related to share-based compensation that is expected to be recognized over a period of up to 6 months.

 

14

 

 

BriaCell Therapeutics Corp

Notes to the Condensed Consolidated Financial Statements

(Unaudited, expressed in US Dollars, except share and per share data and unless otherwise indicated)

 

NOTE 7: SHARE-BASED COMPENSATION (Cont.)

 

c.	The following table summarizes information about the Company’s outstanding and exercisable options granted to employees as of October 31, 2024.

 

Exercise price				Options outstanding as of October 31, 2024				Weighted average remaining contractual term (years)				Options exercisable as of October 31, 2024				Weighted average remaining contractual term (years)				Expiry Date
$	6.03				440,000				3.64				330,000				3.64			June 20, 2028
$	7.16				21,000				3.33				18,375				3.33			February 27, 2028
$	6.04				180,100				2.76				180,100				2.76			August 02, 2027
$	4.71				31,000				2.56				31,000				2.56			May 20, 2027
$	7.51				150,000				2.29				150,000				2.29			February 16, 2027
$	8.47				524,700				2.20				524,700				2.20			January 13, 2027
$	7.15				12,600				2.00				12,600				2.00			November 01, 2026
$	5.74				100,000				1.84				100,000				1.84			September 01, 2026
$	4.24				60,000				1.47				60,000				1.47			April 19, 2026
$	4.24				612,000				1.41				612,000				1.41			March 29, 2026
					2,131,400								2,018,775

 

15

 

 

d.	As result of the Arrangement, 2,131,400 BriaPro Options were issued and are outstanding as of October 31, 2024:

 

Exercise Price				Options outstanding as of October 31, 2024				Options exercisable as of October 31, 2024				Expiry Date
$	0.0933				440,000				330,000			June 20, 2028
$	0.1108				21,000				18,375			February 27, 2028
$	0.0984				180,100				180,100			August 02, 2027
$	0.0729				31,000				31,000			May 20, 2027
$	0.1162				150,000				150,000			February 16, 2027
$	0.1310				524,700				524,700			January 13, 2027
$	0.1165				12,600				12,600			November 01, 2026
$	0.0888				100,000				100,000			September 01, 2026
$	0.0656				60,000				60,000			April 19, 2026
$	0.0656				612,000				612,000			March 29, 2026
					2,131,400				2,018,775

 

e.	Restricted Share Unit Plan

 

The following table summarizes the number of RSU’s granted to directors under the Omnibus plan as of October 31, 2024:

 

		Number of RSU’s outstanding				Aggregate intrinsic value
Balance, July 31, 2024			19,200			$	14,400
Balance, October 31, 2024			19,200			$	15,552

 

f.	The total share-based compensation expense related to all of the Company’s equity-based awards, recognized for the three-month period ended October 31, 2024 and 2023 is comprised as follows:

 

		Three months ended October 31,
		2024				2023
Research and development expenses		$	32,718				257,809
General and administrative expenses			234,253				276,007
Total share-based compensation		$	266,971				533,816

 

16

 

 

BriaCell Therapeutics Corp

Notes to the Condensed Consolidated Financial Statements

(Unaudited, expressed in US Dollars, except share and per share data and unless otherwise indicated)

 

NOTE 8: BASIC AND DILUTED NET LOSS PER SHARE

 

Basic net income (loss) per ordinary share is computed by dividing net income (loss) for each reporting period by the weighted-average number of ordinary shares outstanding during each year. Diluted net income (loss) per ordinary share is computed by dividing net income (loss) for each reporting period by the weighted average number of ordinary shares outstanding during the period, plus dilutive potential ordinary shares considered outstanding during the period, in accordance with ASC No. 260-10 “Earnings Per Share”. The company reported a loss for the three-month period ending October 31, 2023, leading to the exclusion of potentially dilutive ordinary shares. Conversely, a gain was recorded for the three-month period ending October 31, 2024, resulting in the inclusion of all potentially dilutive ordinary shares.

 

		Three months ended October 31,
		2024				2023
		(Unaudited)				(Unaudited)
Basic EPS
Numerator:
Net income (loss)		$	(5,802,175	)		$	6,001,543
Denominator:
Shares used in computation of basic earnings per share			26,641,036				15,981,726
Basic EPS		$	(0.22	)		$	0.38
Diluted EPS
Numerator:
Net income (loss) attributable to common stock, basic		$	(5,802,175	)		$	6,001,543
Adjustment: Change in fair value of warrant liability			-				(14,282,078	)
Net (loss) attributable to common stock, diluted		$	(5,802,175	)		$	(8,280,535	)
Denominator:
Shares used in computing net EPS of common stock, basic			26,641,036				15,981,726
Stock Options			-				211,434
Warrants			-				481,731
Shares used in computation of diluted earnings per share			26,641,036				16,674,891
Diluted EPS		$	(0.22	)		$	(0.50	)

 

NOTE 9: FINANCIAL INCOME (EXPENSES), NET

 

		Three months ended October 31,
		2024				2023
Interest income		$	13,050			$	190,815
Foreign exchange loss			(1,336	)			(10,993	)
Financial income, net		$	11,714			$	179,822

 

NOTE 10: SUBSEQUENT EVENTS

 

a.	Between December 3, 2024 and December 10, 2024, a 620,900 October 2024 Warrants were exercised into 620,900 common shares of the Company, generating gross proceeds of $527,765.

 

b.

On December 13, 2024, the Company closed a public offering for the purchase and sale of 7,400,000 common shares of the Company and warrants to purchase up to an aggregate of 7,400,000 common shares of the Company for aggregate gross proceeds of approximately $5.55 million before deducting underwriting discounts, commissions, and other offering expenses (the “December 2024 Offering”). Each common share was sold together with one warrant to purchase one common share at a combined purchase price of $0.75. The warrants have an exercise price of $0.9375 per share, and are immediately exercisable for a period of five years from the closing date. In addition, the Company issued 370,000 agent warrants. The agent warrants are immediately exercisable for a period of five years from the closing date at an exercise price of $0.9375.

 

17

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

References to the “Company,” “our,” “us” or “we” refer to BriaCell Therapeutics Corp. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the unaudited condensed consolidated financial statements and the notes thereto contained elsewhere in this report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

 

Introduction

 

This Management’s Discussion and Analysis (“MD&A”) should be read together with other information, including our unaudited condensed interim consolidated financial statements and the related notes to those statements included in Part I, Item 1 of this Quarterly Report (the “Condensed Consolidated Financial Statements”), our consolidated financial statements appearing in our Annual Report on Form 10-K for the year ended July 31, 2024 (the “Annual Report”) and Part I, Item 1A, Risk Factors, of the Annual Report. This MD&A provides additional information on our business, recent developments, financial condition, cash flows and results of operations, and is organized as follows:

 

	●	Part 1 - Business Overview. This section provides a general description of our business, which we believe is important in understanding the results of our operations, financial condition, and potential future trends.
	●	Part 2 - Results of Operations. This section provides an analysis of our results of operations for the first quarter of fiscal 2024 in comparison to the first quarter of fiscal 2023.
	●	Part 3 - Financial Liquidity and Capital Resources. This section provides an analysis of our cash flows and outstanding debt and commitments. Included in this analysis is a discussion of the amount of financial capacity available to fund our ongoing operations and future commitments.

 

We prepare and report our unaudited Condensed Consolidated Financial Statements in accordance with U.S. GAAP. Our unaudited Condensed Consolidated Financial Statements, and the financial information contained herein, are reported in U.S Dollars.

 

Cautionary Note Regarding Forward-Looking Statements

 

This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “continue,” or the negative of such terms or other similar expressions. Factors that might cause or contribute to such a discrepancy include, but are not limited to, those described in our other SEC filings.

 

Overview

 

BriaCell is a clinical-stage biotechnology company that is developing novel immunotherapies to transform cancer care. Immunotherapies have come to the forefront in the fight against cancer as they harness the body’s own immune system to recognize and destroy cancer cells. The Company is currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. Bria-IMT™ is currently under Fast Track Designation by the U.S. Food and Drug Administration(the “FDA”) intended to accelerate the review process of novel treatments that address unmet medical needs. Positive completion of the pivotal study, following review by FDA, could lead to full approval of the Bria-IMT™ immune checkpoint inhibitor combination in metastatic breast cancer. BriaCell reported benchmark-beating patient survival and clinical benefit in metastatic breast cancer with median overall survival of 13.4 months in BriaCell’s metastatic breast cancer patients vs. 6.7-9.8 months for similar patients reported in the literature in its Phase 2 study of Bria-IMT™ combination study with retifanlimab at the 2023 San Antonio Breast Cancer Symposium. A completed Bria-IMT™ Phase 1 combination study with retifanlimab (an anti-PD1 antibody manufactured by Incyte) confirmed tolerability and early-stage efficacy. BriaCell is also developing personalized off-the-shelf immunotherapies, Bria-OTS™ and Bria-OTS+™, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which acts both as a stimulator of the immune system as well as an immune checkpoint inhibitor.

 

18

 

 

Recent Developments

 

On October 15, 2024, the Company provided an update on its pivotal Phase 3 study in metastatic breast cancer - 35 clinical sites (18 main and 17 satellite) are active and enrolling patients. Additional sites are in various stages of start-up. Interim data will be analyzed once 144 events (deaths) occur, comparing the overall survival (OS) in patients treated with the Bria-IMT™ combination regimen versus those treated with physician’s choice as the primary endpoint. Positive results of the pivotal Phase 3 study could result in full approval and marketing authorization for Bria-IMT™ in MBC patients. Secondary analyses include comparison of the Bria-IMT™ combination regimen vs Bria-IMT™ monotherapy. BriaCell recently announced impressive Phase 2 survival data in a similar MBC patient population. The Bria-IMT™ combination regimen has received FDA Fast Track designation.

 

On October 22, 2024, the Company reported that in the Company’s Phase 2 clinical study, patients treated with the same Bria-IMT™ regimen formulation being used in the ongoing Phase 3 pivotal trial experienced a one-year survival rate of 55% (i.e. 55% of patients remain alive at least one year after starting on the study). This rate exceeds the survival data of the current standard of care for similar patients (see Table 1). Notably, 4 of 13 patients recruited in 2022 remain in survival follow-up as well.

 

On November, 21, 2024, the Company announced that the first patient was dosed in its Phase 1/2 study (ClinicalTrials.gov identifier: NCT06471673) to evaluate the safety and efficacy of Bria-OTS™, BriaCell’s personalized next generation immunotherapy. The study will investigate Bria-OTS™ alone and in combination with immune check point inhibitor tislelizumab® (manufactured and supplied by BeiGene, Ltd.) for the treatment of metastatic breast cancer. Bria-OTS™ is an enhanced form of Bria-IMT™, currently in pivotal Phase 3 study for metastatic breast cancer.

 

On November 23, 2024, Marc Lustig resigned from the board of directors of the Company.

 

On December 13, 2024, the Company closed a public offering for the purchase and sale of 7,400,000 common shares of the Company and warrants to purchase up to an aggregate of 7,400,000 common shares of the Company for aggregate gross proceeds of approximately $5.55 million before deducting underwriting discounts, commissions, and other offering expenses (the “December 2024 Offering”). Each common share was sold together with one warrant to purchase one common share at a combined purchase price of $0.75. The warrants have an exercise price of $0.9375 per share, and are immediately exercisable for a period of five years from the closing date. In addition, the Company issued 370,000 agent warrants. The agent warrants are immediately exercisable for a period of five years from the closing date at an exercise price of $0.9375.

 

Results of Operations for the Three Months Ended October 31, 2024, and 2023

 

		Three months ended
		October 31,
		2024				2023
Operating expenses:
Research and development expenses		$	3,665,341				6,857,257
General and administrative expenses			1,487,491				1,645,771
Total operating expenses			5,152,832				8,503,028
Operating loss			(5,152,832	)			(8,503,028	)
Financial income, net			11,714				179,822
Change in fair value of the warrant liability			(616,643	)			14,282,078
Share of loss on equity investment			(71,515	)			-
Net income (loss) for the period		$	(5,829,276	)		$	5,958,872
Net loss attributable to non-controlling interest			(27,101	)			(42,671	)
Net income (loss) for the period attributable to BriaCell			(5,802,175	)			6,001,543
Net income (loss) per share attributable to BriaCell – basic		$	(0.22	)		$	0.38
Net income (loss) per share attributable to BriaCell – diluted			(0.22	)			(0.50	)
Weighted average number of shares used in computing net basic earnings per share of common stock			26,641,036				15,619,676
Weighted average number of shares used in computing net diluted earnings per share of common stock			26,641,036				16,674,891

 

Research and Development Costs

 

Research costs are comprised primarily of (i) salaries and wages to Company employees at our laboratory and (ii) clinical trials and investigational drug costs, which include the testing and manufacture of our investigational drugs and costs of our clinical trials.

 

19

 

 

The following is a breakdown of our research and development costs by nature of expenses:

 

		Three months ended October 31,
		2024				2023
Clinical trial sites and investigational drug costs		$	2,439,667			$	5,397,438
Wages and salaries			949,089				1,020,725
Laboratory Rent			114,330				88,480
Supplies			99,430				89,023
Depreciation			22,839				-
Professional fees			7,268				3,782
Share-based compensation			32,718				257,809
		$	3,665,341			$	6,857,257

 

For the three-month period ending October 31, 2024, research costs amounted to $3,665,341, a significant decrease from the $6,857,257 incurred during the same period in 2023. This reduction was primarily driven by lower clinical trial sites and investigational drug costs, which decreased from $5,397,438 in 2023 to $2,439,667 in 2024. The decrease reflects the conclusion of the Bria-IMT™ Phase 1/2a trial and a focus on optimizing expenditures for the pivotal Phase 3 trial. Wages and salaries decreased slightly, from $1,020,725 in 2023 to $949,089 in 2024, reflecting resource allocation adjustments. Laboratory rent increased to $114,330 in 2024, up from $88,480 in 2023, due to expanded use of facilities to support ongoing research. Supplies also increased, from $89,023 in 2023 to $99,430 in 2024, driven by higher operational needs. Depreciation expenses of $22,839 were recognized in 2024, reflecting investments in capital assets to support research activities. Professional fees increased to $7,268 in 2024, compared to $3,782 in 2023, primarily due to consulting and support for clinical operations. Notably, share-based compensation expenses decreased significantly, from $257,809 in 2023 to $32,718 in 2024, contributing to the overall reduction in research and development expenses.

 

Our clinical trial expenses are broken down as follows:

 

		Three months ended October 31,
		2024				2023
Bria-IMT™ Pivotal Phase 3 study		$	2,185,543			$	2,278,258
Bria-IMT™ Phase 1/2a			142,496				1,214,440
Indirect research and development expenses allocated to trials			111,628				134,592
		$	2,439,667			$	3,627,290

 

Clinical trial expenses for the three months ended October 31, 2024, were $2,439,667, compared to $3,627,290 during the same period in 2023. The decrease in expenses is primarily attributable to the conclusion of patient recruitment and related activities in the Bria-IMT™ Phase 1/2a clinical trial in fiscal 2024. This reduction in costs aligns with our transition to the pivotal Phase 3 study of Bria-IMT™, which has become the primary focus of our clinical development efforts.

 

For the three-month period ending October 31, 2024, Bria-IMT™ Pivotal Phase 3 Study costs amounted to $2,185,543, remaining consistent with the prior year’s $2,278,258. This consistency reflects our strategic decision to optimize spending while focusing expenditures on this pivotal trial, underscoring our commitment to prioritizing the Phase 3 study as the cornerstone of our clinical development program. Resources were effectively allocated toward patient recruitment, trial operations, and preparation for key milestones.

 

For the three-month period ending October 31, 2024, Bria-IMT™ Phase 1/2a costs amounted to $142,496, a significant decrease compared to $1,214,440 during the same period in 2023. This decrease is attributed to the trial’s conclusion in fiscal 2024, with only minimal remaining expenses related to final data analysis and study close-out activities.

 

For the three-month period ending October 31, 2024, indirect research and development expenses allocated to trials amounted to $111,628, compared to $134,592 in the prior year. This reduction is primarily due to streamlined trial operations and a shift in resource allocation toward the pivotal Phase 3 study.

 

We remain focused on advancing the pivotal Phase 3 study of Bria-IMT™ in advanced breast cancer and continue to direct resources accordingly to ensure its timely progression.

 

General and Administrative Expenses

 

For the three-month period ending October 31, 2024, general and administrative expenses amounted to $1,487,491, showing a decrease from $1,645,771 in the same period of 2023. The decrease in general and administrative expenses primarily stems from lower insurance premiums, professional fees and share-based compensation expenses. The Company has reduced general and administrative expenses in order to devote more resources to its clinical program.

 

Financial income (expenses), net

 

For the three-month period ending October 31, 2024, net financial income amounted to $11,714, a significant decrease from the $179,822 recorded in the same period of 2023. Financial income for the three-month period ending October 31, 2024 primarily consists of interest income of $13,050, offset by a foreign exchange loss of $1,336. In comparison, For the three-month period ending October 31, 2023, interest income was $190,815, while foreign exchange losses totaled $10,993. The decrease in financial income from 2023 to 2024 reflects lower interest income due to reduced cash and cash equivalents available for investment in interest-bearing funds

 

Profit (loss) for the period

 

For the three-month period ended October 31, 2024, the Company reported a loss of $5,829,276 compared to a gain of $5,958,872 for the same period in 2023. The loss in the three-month period ended October 31, 2024, primarily resulted from the significant change in the fair value of the warrant liability, which accounted for a loss of $616,643 in 2024 compared to a gain of $14,282,078 in 2023. This highlights the substantial impact that warrant liability valuation has on the Company’s overall financial performance, despite decreased operational spending during the period, particularly in research and development.

 

20

 

 

Liquidity, Capital Resources and Going Concern Uncertainty

 

The financial statements have been prepared on a going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The continuing operations of the Company are dependent upon its ability to continue to raise adequate financing and to commence profitable operations in the future.

 

As of October 31, 2024, and a positive working capital balance of $3,230,459 (July 31, 2024 negative balance of $3,807,303).

 

As of October 31, 2024, the Company has total assets of $10,414,330 (July 31, 2024 - $5,872,261), a positive working capital of $3,230,459 (July 31, 2024 – negative balance of $3,807,303) and an accumulated deficit of $91,245,872 (July 31, 2024 - $85,443,697).

 

As of October 31, 2024, the Company’s capital resources consist primarily of cash and cash equivalents, comprising mostly of cash on deposit with banks, investments in money market funds, investments in U.S. government securities, U.S. government agency securities, and investment grade corporate debt securities. Our investment policy and strategy are focused on preservation of capital and supporting our liquidity requirements.

 

Historically, the Company has financed its operation through private and public placement of equity securities, as well as debt financing. The Company’s ability to fund its longer-term cash requirements is subject to multiple risks, many of which are beyond its control. The Company intends to raise additional capital, either through debt or equity financings in order to achieve its business plan objectives. Management believes that it can be successful in obtaining additional capital; however, there can be no assurance that the Company will be able to do so. There is no assurance that any funds raised will be sufficient to enable the Company to attain profitable operations or continue as a going concern. To the extent that the Company is unsuccessful, the Company may need to curtail or cease its operations and implement a plan to extend payables or reduce overhead until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful. To this end, for several months during calendar year 2024, certain directors and officers agreed to defer payment of their directors’ fees/compensation until we completed a financing, after which, these fees were paid in full. Further, certain officers have indicated their willingness to receive a portion of their compensation in equity of the Company, subject to applicable Nasdaq rules. In addition, we continue to reduce expenditure on certain non-core activities whilst maintaining our focus on our Phase 3 Bria-IMT™ pivotal study in advanced metastatic breast cancer.

 

During the period ended October 31, 2024, the Company’s overall position of cash and cash equivalents increased by $4,930,176 from the period ended July 31, 2024 (including effects of foreign exchange). This increase in cash can be attributed to the following:

 

The Company’s net cash used in operating activities during the period ended October 31, 2024, was $6,955,076 as compared to $7,605,245 for the period ended October 31, 2023.

 

Cash gained in financing activities for the period ended October 31, 2024, was 11,960,252 as compared to nil for the period ended October 31, 2023.

 

21

 

 

Off-Balance Sheet Arrangements

 

None.

 

Tabular Disclosure of Contractual Obligations

 

None.

 

Critical Accounting Policies and Estimates

 

There have been no material changes to our critical accounting policies and estimates from the information provided in the MD&A section in our Annual Report.

 

New Accounting Policies Adopted

 

The Company did not adopt any new accounting policies during the period ended October 31, 2024.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

The Company’s financial instruments consist of cash and cash equivalents, investments, warrant liability, short term loans, trade payable, and accrued expenses and other payables. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest or credit risks arising from these financial instruments. The fair value of these financial instruments approximates their carrying values, unless otherwise noted.

 

Management understands that the Company is exposed to financial risk arising from fluctuations in foreign exchange rates and the degree of volatility of these rates as a portion of the Company’s transactions occur in Canadian Dollars (mainly costs relating to being a public company in Canada), and the Company’s functional and presentation currency is the US dollar. The Company does not use derivative instruments to reduce its exposure to foreign currency risk.

 

The Company is exposed in varying degrees to a variety of financial instrument related risks. The Board of Directors approves and monitors the risk management process. The overall objectives of the Board are to set policies that seek to reduce risk as far as possible without unduly affecting the Company’s competitiveness and flexibility.

 

The type of risk exposure and the way in which such exposure is managed is as follows:

 

Credit risk

 

The Company has no significant concentration of credit risk arising from operations. Management believes that the credit risk concentration with respect to financial instruments is remote.

 

Liquidity Risk

 

The Company’s approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities as they come due. As of October 31, 2024, the Company has total assets of $10,414,330 (July 31, 2024 - $5,872,261) and a positive working capital balance of $3,230,459 (July 31, 2024 - negative working capital balance of $3,807,303).

 

Market Risk

 

Interest rate risk

 

Interest Rate risk is the risk that the fair value of a financial instrument will fluctuate because of changes in market interest rates. Loans payable include both fixed and variable interest rates; however, the Company does not believe it is exposed to material interest rate risk.

 

Price risk

 

As the Company has no revenues, price risk is remote.

 

22

 

 

Exchange risk

 

The Company is exposed to foreign exchange risk as a portion of the Company’s transactions occur in Canadian Dollars (mainly costs relating to being a public company in Canada) and, therefore, the Company is exposed to foreign currency risk at the end of the reporting period through its Canadian denominated accounts payable and cash. As of October 31, 2024, a 5% depreciation or appreciation of the Canadian dollar against the US dollar would not have a material effect on the in total loss and comprehensive loss.

 

Fair Values

 

The carrying values of cash and cash equivalents, trade payable, warrant liability, short term loans, and accrued expenses and other payables approximate their fair values due to their short terms to maturity.

 

Cash and cash equivalents are valued using quoted market prices in active markets. The fair value of the warrant liability is determined based on the nature of the warrant. For publicly traded warrants we use the quoted market price and for all other warrants we use the Black-Scholes pricing model.

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

We maintain “disclosure controls and procedures,” as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.

 

Our management, with the participation of our principal executive officer and principal accounting and financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 under the Securities Exchange Act of 1934, as amended, or the Exchange Act), as of the end of the period covered by this Quarterly Report on Form 10-Q. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on such evaluation, our principal executive officer and principal accounting and financial officer have concluded that as of October 31, 2024, our disclosure controls and procedures were effective at the reasonable assurance level.

 

Changes in Internal Control over Financial Reporting

 

There have not been material changes in our internal control over financial reporting during the quarter ended October 31, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

None.

 

Item 1A. Risk Factors.

 

As of the date of this Quarterly Report on Form 10-Q, there have been no material changes from the risk factors previously disclosed in our Annual Report for the year ended July 31, 2024.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

There were no unregistered sales of equity securities during the three months ended October 31, 2024.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not Applicable.

 

23

 

 

Item 5. Other Information.

 

None.

 

Item 6. Exhibits

 

The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.

 

EXHIBIT INDEX

 

Exhibit		Description
31.1		Certification of Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *
31.2		Certification of Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *
32.1		Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 *
32.2		Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 *
101.INS		Inline XBRL Instance Document*
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document*
101.SCH		Inline XBRL Taxonomy Extension Schema Document*
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document*
101.LAB		Inline XBRL Taxonomy Extension Labels Linkbase Document*
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document*
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

*	Filed herewith.

 

24

 

 

SIGNATURES

 

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	BRIACELL THERAPEUTICS CORP.
December 16, 2024	By:	/s/ William V. Williams
	Name:	William V. Williams
	Title:	Chief Executive Officer
		(Principal Executive Officer)
December 16, 2024	By:	/s/ Gadi Levin
	Name:	Gadi Levin
	Title:	Chief Financial Officer
		(Principal Financial and Accounting Officer)

 

25

 

Exhibit 31.1

 

CERTIFICATIONS

 

I, William V. Williams, certify that:

 

1.	I have reviewed this Quarterly Report on Form 10-Q of BriaCell Therapeutics Corp.;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

December 16, 2024	/s/ William V. Williams
	William V. Williams
	President and Chief Executive Officer (Principal Executive Officer)

 

 

Exhibit 31.2

 

CERTIFICATIONS

 

I, Gadi Levin, certify that:

 

1.	I have reviewed this Quarterly Report on Form 10-Q of BriaCell Therapeutics Corp.;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

December 16, 2024	/s/ Gadi Levin
	Gadi Levin
	Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

 

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

I, William V. Williams, President and Chief Executive Officer of BriaCell Therapeutics Corp. (the “Company”), hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

 

1.	The Quarterly Report on Form 10-Q of the Company for the period ended October 31, 2024 (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

December 16, 2024	/s/ William V. Williams
	William V. Williams
	President and Chief Executive Officer (Principal Executive Officer)

 

 

Exhibit 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Gadi Levin, Chief Financial Officer of BriaCell Therapeutics Corp. (the “Company”), hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

 

1.	The Quarterly Report on Form 10-Q of the Company for the period ended October 31, 2024 (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

December 16, 2024	/s/ Gadi Levin
	Gadi Levin
	Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

 

Cover - shares	3 Months Ended
	Oct. 31, 2024	Dec. 16, 2024
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Oct. 31, 2024
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2025
Current Fiscal Year End Date	--07-31
Entity File Number	001-40101
Entity Registrant Name	BRIACELL THERAPEUTICS CORP.
Entity Central Index Key	0001610820
Entity Tax Identification Number	47-1099599
Entity Incorporation, State or Country Code	A1
Entity Address, Address Line One	235 15th Street, Suite 300
Entity Address, City or Town	West Vancouver
Entity Address, State or Province	BC
Entity Address, Postal Zip Code	V7T 2X1
City Area Code	604
Local Phone Number	921-1810
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	true
Entity Common Stock, Shares Outstanding		44,204,161
Common Stock [Member]
Title of 12(b) Security	Common shares, no par value
Trading Symbol	BCTX
Security Exchange Name	NASDAQ
Warrants To Purchase Common Shares No Par Value [Member]
Title of 12(b) Security	Warrants to purchase common shares, no par value
Trading Symbol	BCTXW
Security Exchange Name	NASDAQ

Condensed Consolidated Balance Sheets - USD ($)	Oct. 31, 2024	Jul. 31, 2024
CURRENT ASSETS:
Cash and cash equivalents	$ 5,792,265	$ 862,089
Amounts receivable and prepaid expenses	2,426,830	2,791,765
Total current assets	8,219,095	3,653,854
NON-CURRENT ASSETS:
Equity Investment in BC Therapeutics	421,975	418,490
Intangible assets, net	195,978	199,796
Property and equipment, net	365,336	388,175
Long term prepaid expenses	1,211,946	1,211,946
Total non-current assets	2,195,235	2,218,407
Total assets	10,414,330	5,872,261
CURRENT LIABILITIES:
Trade payables	4,233,968	7,170,781
Accrued expenses and other payables	754,668	290,376
Total current liabilities	4,988,636	7,461,157
NON-CURRENT LIABILITIES:
Warrant liability	1,712,679	1,096,036
Total non-current liabilities	1,712,679	1,096,036
SHAREHOLDERS’ EQUITY (DEFICIT):
Share capital of no par value - Authorized: unlimited at October 31, 2024 and July 31, 2024, Issued and outstanding: 36,183,161 shares October 31, 2024 and 18,284,661 July 31, 2024, respectively	82,040,741	72,166,414
Share-based payment reserved	9,456,232	9,189,261
Warrant reserve	3,930,221	1,844,296
Accumulated other comprehensive loss	(138,684)	(138,684)
Non-controlling interest	(329,623)	(302,522)
Accumulated deficit	(91,245,872)	(85,443,697)
Total shareholders’ equity (deficit)	3,713,015	(2,684,932)
Total liabilities and shareholders’ equity	$ 10,414,330	$ 5,872,261

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	3 Months Ended	12 Months Ended
	Oct. 31, 2024	Jul. 31, 2024
Statement of Financial Position [Abstract]
Common stock, no par value	$ 0	$ 0
Common stock, shares authorized, unlimited	Unlimited	Unlimited
Common stock, shares issued	36,183,161	18,284,661
Common stock, shares outstanding	36,183,161	18,284,661

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Operating expenses:
Research and development expenses	$ 3,665,341	$ 6,857,257
General and administrative expenses	1,487,491	1,645,771
Total operating expenses	5,152,832	8,503,028
Operating loss	(5,152,832)	(8,503,028)
Financial income, net	11,714	179,822
Change in fair value of the warrant liability	(616,643)	14,282,078
Share of loss on equity investment	(71,515)
Net income (loss) for the period	(5,829,276)	5,958,872
Net loss attributable to non-controlling interest	(27,101)	(42,671)
Net income (loss) for the period attributable to BriaCell	$ (5,802,175)	$ 6,001,543
Net income (loss) per share attributable to BriaCell – basic	$ (0.22)	$ 0.38
Net income (loss) per share attributable to BriaCell – diluted	$ (0.22)	$ (0.50)
Weighted average number of shares used in computing net basic earnings per share of common stock	26,641,036	15,981,726
Weighted average number of shares used in computing net diluted earnings per share of common stock	26,641,036	16,674,891
Balance	$ (2,684,932)	$ (3,777,181)
Instruments issued to minority shareholders at the Arrangement Date		(199,207)
Issuance of options	266,971	533,816
Income (loss) for the period	(5,829,276)	5,958,872
Balance	3,713,015	2,516,300
Common Stock [Member]
Operating expenses:
Net income (loss) for the period
Balance	$ 72,166,414	$ 69,591,784
Balance, shares	18,284,661	15,981,726
Instruments issued to minority shareholders at the Arrangement Date
Issuance of options
Income (loss) for the period
Balance	$ 82,040,741	$ 69,591,784
Balance, shares	36,183,161	15,981,726
Warrant [Member]
Operating expenses:
Net income (loss) for the period
Balance	1,844,296
Issuance of options
Income (loss) for the period
Balance	3,930,221
Additional Paid-in Capital [Member]
Operating expenses:
Net income (loss) for the period
Balance	9,189,261	7,421,950
Instruments issued to minority shareholders at the Arrangement Date		(36,767)
Issuance of options	266,971	533,816
Income (loss) for the period
Balance	9,456,232	7,918,999
AOCI Attributable to Parent [Member]
Operating expenses:
Net income (loss) for the period
Balance	(138,684)	(138,684)
Instruments issued to minority shareholders at the Arrangement Date
Issuance of options
Income (loss) for the period
Balance	(138,684)	(138,684)
Retained Earnings [Member]
Operating expenses:
Net income (loss) for the period	(5,802,175)	6,001,543
Balance	(85,443,697)	(80,652,231)
Instruments issued to minority shareholders at the Arrangement Date
Issuance of options
Income (loss) for the period	(5,802,175)	6,001,543
Balance	(91,245,872)	(74,650,688)
Noncontrolling Interest [Member]
Operating expenses:
Net income (loss) for the period	(27,101)	(42,671)
Balance	(302,522)
Instruments issued to minority shareholders at the Arrangement Date		(162,440)
Issuance of options
Income (loss) for the period	(27,101)	(42,671)
Balance	$ (329,623)	$ (205,111)

Condensed Consolidated Statements of Changes in Shareholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Warrant [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance at Jul. 31, 2023	$ 69,591,784	$ 7,421,950		$ (138,684)	$ (80,652,231)		$ (3,777,181)
Balance, shares at Jul. 31, 2023	15,981,726
Issuance of Options		533,816					533,816
Net loss for the period					6,001,543	(42,671)	5,958,872
Balance at Oct. 31, 2023	$ 69,591,784	7,918,999		(138,684)	(74,650,688)	(205,111)	2,516,300
Balance, shares at Oct. 31, 2023	15,981,726
Balance at Jul. 31, 2024	$ 72,166,414	9,189,261	1,844,296	(138,684)	(85,443,697)	(302,522)	(2,684,932)
Balance, shares at Jul. 31, 2024	18,284,661
Issuance of Options		266,971					266,971
Exercise of prefunded warrants
Exercise of prefunded warrants, shares	100,000
Exercise of broker warrants	$ 442,677		(149,426)				293,251
Exercise of broker warrants, shares	345,000
Issuance of units	$ 9,431,650		2,235,351				11,667,001
Issuance of shares, shares	17,453,500
Net loss for the period					(5,802,175)	(27,101)	(5,829,276)
Balance at Oct. 31, 2024	$ 82,040,741	$ 9,456,232	$ 3,930,221	$ (138,684)	$ (91,245,872)	$ (329,623)	$ 3,713,015
Balance, shares at Oct. 31, 2024	36,183,161

Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Oct. 31, 2024	Oct. 31, 2023	Jul. 31, 2024
Cash flow from operating activities
Net income (loss) for the period	$ (5,829,276)	$ 5,958,872
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization	3,818	3,818
Depreciation	22,839
Share-based compensation	266,971	533,816
Equity losses	71,515
Change in fair value of warrants	616,643	(14,282,078)
Changes in assets and liabilities:
Decrease (increase) in amounts receivable	736,788	(2,537)
(Increase) decrease in prepaid expenses	(371,853)	937,816
Decrease in accounts payable	(2,936,813)	(689,824)
Increase (decrease) in accrued expenses and other payables	464,292	(65,128)
Total cash flow from operating activities	(6,955,076)	(7,605,245)
Cash flows from Investing activities
Equity investment in BC Therapeutics	(75,000)
Total cash flow from investing activities	(75,000)
Cash flows from financing activities
Proceeds from exercise of warrants	293,251
Proceeds from the issuance of shares, net of issuance costs	11,667,001
Total cash flow from financing activities	11,960,252
Increase (decrease) in cash and cash equivalents	4,930,176	(7,605,245)
Cash and cash equivalents at beginning of the period	862,089	21,251,092	$ 21,251,092
Cash and cash equivalents at end of the period	$ 5,792,265	$ 13,645,847	$ 862,089

GENERAL AND GOING CONCERN	3 Months Ended
	Oct. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GENERAL AND GOING CONCERN	NOTE 1: GENERAL AND GOING CONCERN     a. BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) was incorporated under the Business Corporations Act (British Columbia) on July 26, 2006 and is listed on the Toronto Stock Exchange (“TSX”) under the symbol “BCT”. The Company also trades on the Nasdaq Capital Market (“NASDAQ”) under the symbols “BCTX” and “BCTXW”.         b. BriaCell is an immuno-oncology biotechnology company. The Company is currently advancing its Bria-IMT targeted immunotherapy program against end-stage breast cancer to Phase 3 study which has been approved by the FDA. BriaCell is also developing a personalized off-the-shelf immunotherapy, Bria-OTS™, and a soluble CD80 protein therapeutic which acts both as a stimulator of the immune system as well as an immune checkpoint inhibitor.         c. Basis of presentation of the financial statements:           The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X promulgated by the U.S Securities and Exchange Commission (the “SEC”). Certain information or footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments consisting of a normal recurring nature which are necessary for a fair presentation of the financial position, operating results, and cash flows for the periods presented.           The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report for the year ended July 31, 2024, filed with the SEC on October 28, 2024. The interim period results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year.     d. Going concern   The Company continues to devote substantially all of its efforts toward research and development activities. In the course of such activities, the Company has sustained operating losses and expects such losses to continue in the foreseeable future. The Company’s accumulated deficit as of October 31, 2024 was $91,245,872 and negative cash flows from operating activities during the three-month period ended October 31, 2024 was $6,955,076. The Company is planning to finance its operations by exploring additional sources of capital and financing, while managing its existing working capital resources. The Company’s ability to continue as a going concern is dependent upon its ability to attain future profitable operations and to obtain the necessary financing to meet its obligations arising from normal business operations when they come due. The uncertainty of the Company’s ability to raise such financial capital casts substantial doubt on the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company not be able to continue as a going concern. See note 5(b) for details of an $8.5 million gross and $5.0 million gross offering that was completed in September 2024 and October 2024, respectively.         e. The Company has two wholly-owned U.S. subsidiaries: (i) BriaCell Therapeutics Corp. (“BTC”), which was incorporated in April 3, 2014, under the laws of the state of Delaware, and (ii) BTC has a wholly-owned subsidiary, Sapientia Pharmaceuticals, Inc. (“Sapientia”), which was incorporated in September 20, 2012, under the laws of the state of Delaware. The Company also has one Canadian subsidiary: BriaPro Therapeutics Corp, (“BriaPro”) which was incorporated on May 15, 2023, under the Business Corporations Act (British Columbia). See also note 1f. (Sapientia and BTC and BriaPro together, the “Subsidiaries”).         f. On August 31, 2023, the Company closed a plan of arrangement spinout transaction (the “Arrangement”) pursuant to which certain pipeline assets of the Company, including Bria-TILsRx™ and protein kinase C delta (PKCδ) inhibitors for multiple indications including cancer (the “BriaPro Assets”), were spun-out to BriaPro Therapeutics Corp. (“BriaPro”), resulting in a 2/3rd owned subsidiary of the Company with the remaining 1/3rd held by BriaCell shareholders (“BriaCell Shareholders”).           Pursuant to the terms of the Arrangement, BriaPro has acquired the entire right and interest in and to the BriaPro Assets in consideration for the issuance by BriaPro to the Company of BriaPro common shares. Under the terms of the Arrangement, for each BriaCell share held immediately prior to closing, BriaCell Shareholders receive one (1) common share of BriaPro, and one (1) new common share of BriaCell (retiring their old share) having the same terms and characteristics as the existing BriaCell common shares. The Company will remain listed on the NASDAQ Stock Market and Toronto Stock Exchange, and BriaPro is an unlisted reporting issuer in Canada.   Immediately following the closing of the Arrangement, the Company controls 2/3rd of the BriaPro common shares representing approximately 66.6% of the issued and outstanding common shares of BriaPro.   As a result of the Arrangement, there are 47,945,178 BriaPro common shares issued and outstanding. The Company now beneficially owns or controls approximately 31,963,452 BriaPro common shares, representing 2/3rd of the issued and outstanding BriaPro common shares.   Pursuant to the Arrangement, each BriaCell warrant in issuance at the time of the Arrangement shall, in accordance with its terms, entitle the holder thereof to receive, upon the exercise thereof, one BriaCell Share and one BriaPro Share for the original exercise price. Warrants issued by the Company, subsequent to the Arrangement are not subject to the terms above.   Upon the exercise of BriaCell Warrants, BriaCell shall, as agent for BriaPro, collect and pay to BriaPro an amount for each one (1) BriaPro Share so issued that is equal to the exercise price under the BriaCell Warrant multiplied by the fair market value of one (1) BriaPro Share at the Effective Date divided by the total fair market value of one (1) BriaCell Share and one (1) BriaPro Share at the Effective Date (“BriaPro Warrant Shares”).   Pursuant to the Arrangement, all Briacell option holders received the same amount of BriaPro options (“BriaPro Option”) and under the BriaPro incentive plan. The exercise price of the BriaCell options was apportioned between the BriaCell options and the BriaPro options, as follows:   Each one (1) BriaPro Option to acquire one (1) Share shall have an exercise price equal to the product obtained by multiplying the original exercise price of the BriaCell Option by the quotient obtained by dividing (A) the fair market value of a BriaPro Share at the Effective Date by (B) the aggregate fair market value of a BriaCell Share and a BriaPro Share at the Effective Date.   Pursuant to the Arrangement, all BriaCell Restricted Shares Units (“RSU”) holders received the same amount of BriaPro RSU’s under the BriaPro incentive plan.   Transition Services Agreement   On August 31, 2023, the Company and BriaPro executed a transition services agreement (the “Agreement”), pursuant to which BriaCell will provide certain research and development and head office services (the “Services”) to BriaPro for a fixed monthly fee of $20,000.   Briacell and BriaPro acknowledged the transitional nature of the Services and accordingly, as promptly as practicable, BriaPro agreed to use commercially reasonable efforts to transition each Service to its own internal organization or to obtain alternate third party providers to provide the Services.   In accordance with US GAAP’s Accounting Standards Codification 505 “Equity”, the Arrangement was determined to be a spinoff of nonmonetary assets which did not constitute a business. However, since the assets were transferred to an entity under the Company’s control, the assets is being recorded on the Company’s basis (carry value) and not at fair market value.     BriaCell Therapeutics Corp Notes to the Condensed Consolidated Financial Statements (Unaudited, expressed in US Dollars, except share and per share data and unless otherwise indicated)

SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Oct. 31, 2024
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2: SIGNIFICANT ACCOUNTING POLICIES   a. Use of estimates:       The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company’s management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities at the dates of the condensed consolidated financial statements, and the reported amount of expenses during the reporting periods. Actual results could differ from those estimates.   b. Prepaid expenses       The Company has prepaid certain expenses in respect of its pivotal phase III trial and estimates the period over which such expenses will be incurred. As of July 31, 2024, the Company revised its estimate of the time to completion in respect of this trial. Amounts estimated to be expenses in more than 12 months have been classified to long-term prepaid expenses.   c. The useful life of property and equipment       Property and equipment are depreciated over their useful lives. Useful lives are based on management’s estimates of the period that the assets will be used which are periodically reviewed for continued appropriateness. Changes to estimates can result in significant variations in the amounts charged to the consolidated statement of operations and comprehensive loss in specific periods.   d. Investment equity method:       Investments in entities over which the Company does not have a controlling financial interest but has significant influence are accounted for using the equity method, with the Company’s share of losses reported in the loss from equity method investments on the statements of operation and comprehensive loss. The Company has a 54.6% interest in BC Therapeutics. Management evaluates whether it has control over the investee in accordance with the guidance of ASC 810, which requires judgment to assess factors such as power over significant activities of the investee, exposure to variable returns, and the ability to affect those returns. Based on this evaluation, management determines whether control or significant influence is present for accounting purposes.   e. Recently issued and adopted accounting standards:       As an “emerging growth company,” the Jumpstart Our Business Startups Act (“JOBS Act”) allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this extended transition period under the JOBS Act. The adoption dates discussed below reflect this election. The pronouncements below relate to standards that impact the Company.       1. In December 2023, the FASB issued ASU 2023-09 - Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This standard modifies the rules on income tax disclosures to require entities to disclose specific categories in the rate reconciliation, the income or loss from continuing operations before income tax expense or benefit, and income tax expense or benefit from continuing operations. ASU 2023-09 also requires entities to disclose their income tax payments to international, federal, state, and local jurisdictions. The ASU is effective for years beginning after December 15, 2024, but early adoption is permitted. This ASU should be applied on a prospective basis, although retrospective application is permitted. The Company is currently evaluating the impact of this standard on its financial statements and disclosures.         2. In March 2024, the FASB issued ASU 2024-01 - Compensation—Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar Awards. This standard clarifies whether profits interest and similar awards fall within the scope of stock-based compensation guidance as defined in ASC Topic 718, introducing examples to demonstrate this. The ASU includes scenarios where profits interest awards are classified as equity instruments or liability awards and situations where they fall outside ASC Topic 718, being accounted for under ASC Topic 710. The ASU is effective for years beginning after December 15, 2024, but early adoption is permitted. This ASU should be applied on a prospective basis, although retrospective application is permitted. The Company is currently evaluating the impact of this standard on its financial statements and disclosures.     BriaCell Therapeutics Corp Notes to the Condensed Consolidated Financial Statements (Unaudited, expressed in US Dollars, except share and per share data and unless otherwise indicated)

INVESTMENT IN BC THERAPEUTICS INC.	3 Months Ended
	Oct. 31, 2024
Investments, All Other Investments [Abstract]
INVESTMENT IN BC THERAPEUTICS INC.	NOTE 3: INVESTMENT IN BC THERAPEUTICS INC.       On December 21, 2021, the Company and BC Therapeutics, Inc. (“BC Therapeutics” or “the Investee”) entered a share purchase agreement (“SPA”), pursuant to which the Company initially provided a loan of $300,000 to BC Therapeutics, with no interest to be paid. Subsequently, in accordance with the SPA, this loan was converted into an equity investment in BC Therapeutics at a rate of $1.25 per share, resulting in a 37.5% ownership interest (“Initial Investment”).           Pursuant to the SPA (“Initial Investment”), Briacell also received two options to invest an additional $225,000 per option at $1.25 per BC Therapeutics share. The first option expired on February 15, 2024 (“First BC Therapeutics Option”) and the second option expired on June 30, 2024 (“Second BC Therapeutics Options”, together, the “BC Therapeutic Options”). In accordance with ASC 321 and ASC 815, the BC Therapeutics Options were valued at $76,350 in accordance with the Black Scholes Option Price Model, using the following assumptions: Share price: $1.25, Exercise price: $1.25, Dividend yield: 0%, Risk free interest rate: 4.902%, Volatility: 100%.           BC Therapeutics has a board of four representatives, with two representatives appointed by BriaCell and two representatives appointed by the existing shareholders. All significant decisions related to BC Therapeutics require the approval of at least a majority of the board members.           The Company initially acquired a significant interest in BC Therapeutics on February 1, 2024, by exercising the First BC Therapeutics Option, increasing its ownership to 51.2%. On August 7, 2024, following the expiration of the original Second BC Therapeutics Option, the Company and BC Therapeutics amended the SPA to introduce new options, allowing the exercise in tranches of at least 20,000 shares at $1.25 per share. During the quarter ended October 31, 2024, the Company exercised this option in three tranches, totaling $75,000 for 60,000 shares. As of October 31, 2024, the Company holds 480,000 shares in BC Therapeutics, representing 54.6% of the total issued and outstanding shares.           In accordance with ASC 810, the Company continues to account for the investment under the equity method of accounting as the Company does not exercise control over BC Therapeutics.   Changes in the Company’s equity investment in BC Therapeutics is summarized as follows:   Balance – August 1, 2023   $ -   Funding (including the value of the BC Therapeutics Options)     525,000   Share of losses     (106,510 ) Balance – July 31, 2024     418,490   Funding     75,000   Share of losses     (71,515 ) Balance – October 31, 2024   $ 421,975     The following amounts represent the Company’s 54.6% share of the assets of BC Therapeutics:        As of October 31, 2024   Current assets: Cash   $ 2,805   Net assets   $ 2,805       BriaCell Therapeutics Corp Notes to the Condensed Consolidated Financial Statements (Unaudited, expressed in US Dollars, except share and per share data and unless otherwise indicated)

CONTINGENT LIABILITIES AND COMMITMENTS	3 Months Ended
	Oct. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
CONTINGENT LIABILITIES AND COMMITMENTS	NOTE 4: CONTINGENT LIABILITIES AND COMMITMENTS     a. BriaPro Warrants           Upon the exercise of BriaCell Warrants, BriaCell shall, as agent for BriaPro, collect and pay to BriaPro an amount based on an agreed formula (detailed in note 1(f)). As of October 31, 2024, this amount totaled up to $241,164 and is eliminated on consolidation.         b. Lease           The Company was previously in a 12-month commitment for office and lab space in Philadelphia, PA, costing approximately $38,110 per month. The lease expired on August 31, 2024, and as of October 2024, the Company continues to occupy the space on a month-to-month basis under the same terms.

FAIR VALUE MEASUREMENTS	3 Months Ended
	Oct. 31, 2024
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 5: FAIR VALUE MEASUREMENTS   The following table presents information about our financial instruments that are measured at fair value on a recurring basis as of October 31, 2024 and July 31, 2024:       Fair Value Measurements at       October 31, 2024     July 31, 2024       Level 1     Level 2     Total     Level 1     Level 2     Total   Financial Assets:                                                 Cash and cash equivalents     5,792,265       -       5,792,265       862,089       -       862,089                                                     Total assets measured at fair value   $ 5,792,265     $ -     $ 5,792,265     $ 862,809     $ -     $ 862,089                                                     Financial liabilities:                                                 Warrants liability     1,207,621       505,058       1,712,679       760,657       335,379       1,096,036                                                     Total liabilities measured at fair value   $ 1,207,621     $ 505,058     $ 1,712,679     $ 760,657     $ 335,379     $ 1,096,036     We classify our cash and cash equivalents and the liability in respect of publicly traded warrants within Level 1 because we use quoted market prices in active markets.   The fair value of the warrant liability for non-public warrants is measured using inputs other than quoted prices included in Level 1 that are observable for the liability either directly or indirectly, and thus are classified as Level 2 financial instruments.     BriaCell Therapeutics Corp Notes to the Condensed Consolidated Financial Statements (Unaudited, expressed in US Dollars, except share and per share data and unless otherwise indicated)

SHAREHOLDERS’ EQUITY	3 Months Ended
	Oct. 31, 2024
Equity [Abstract]
SHAREHOLDERS’ EQUITY	NOTE 6: SHAREHOLDERS’ EQUITY   a. Authorized share capital   The authorized share capital consists of an unlimited number of common shares with no par value. b. Issued share capital     (i) The Company issued the following shares during the three-month period ended October 31, 2024:     1. On September 12, 2024, the Company completed a registered direct offering for the purchase and sale of 12,325,000 common shares of the Company at an offering price of $0.69 per share, for aggregate gross proceeds of approximately $8.5 million before deducting placement agent fees and other offering expenses (the “September 2024 Offering”).           In connection with the September 2024 Offering, the Company issued 616,250 placement agent warrants with an exercise price of $0.8625 per share. These placement agent warrants are exercisable beginning on March 11, 2025, and expire five years from the date of issuance. The fair value of the broker warrants was determined to be $247,800 using the Black-Scholes option pricing model, with the following assumptions: share price - $0.63; exercise price - $0.8625; expected life – 5 years; annualized volatility - 109%; dividend yield - 0%; risk-free rate – 3.469%, non-marketability discount – 16.38%.           The amount was credited to the warrant reserve at the date of the September 2024 Offering.   2. On October 2, 2024, the Company closed a registered direct offering for the purchase and sale of 5,128,500 common shares of the Company and warrants to purchase up to an aggregate of 5,128,500 common shares of the Company for aggregate gross proceeds of $5 million before deducting placement agent fees and other offering expenses (the “October 2024 Offering”). Each common share was sold together with one warrant to purchase one common share at a combined purchase price of $0.975. The warrants have an exercise price of $0.85 per share, are immediately exercisable, and expire five years from the date of issuance (“October 2024 Warrants”).   In connection with the October 2024 Offering, the Company issued 256,425 placement agent warrants. The placement agent warrants are immediately exercisable at an exercise price of $1.21875 per share and expire five years from the date of issuance.   The fair value of the 5,128,500 October 2024 Warrants was determined to be $2,211,266 using the Black-Scholes option pricing model, with the following assumptions: share price - $0.54; exercise price - $0.85; expected life – 5 years; annualized volatility - 121%; dividend yield - 0%; risk-free rate – 3.553%.   The fair value of the 256,425 placement agent warrants was determined to be $204,128 using the Black-Scholes option pricing model, with the following assumptions: share price - $1.01; exercise price - $1.22; expected life – 5 years; annualized volatility - 112%; dividend yield - 0%; risk-free rate – 3.561%.   The amounts were credited to the warrant reserve at the date of the October 2024 Offering.   During October 2024, 345,000 October 2024 Warrants with an exercise price of $0.85 were exercised for gross proceeds of $293,250. The Company issued 345,000 common shares in respect of the exercise of these warrants.     c. Share Purchase Warrants   A summary of changes in share purchase warrants for the three-month period ending October 31, 2024 is presented below:       Number of options outstanding     Weighted average exercise price (*)   Balance, July 31, 2024     10,524,585     $ 4.92   Exercised     (345,000 )     (0.85 ) Granted in the October 2024 Offering     5,128,500       0.85   Balance, October 31, 2024     15,308,085     $ 3.65       (ii) As of October 31, 2024, warrants outstanding were as follows:   Number of Warrants     Exercise Price(*)     Exercisable At October 31, 2024     Expiry Date   51,698     $ 3.89       51,698     November 16, 2025   3,896,809     $ 5.31       3,896,809     February 26, 2026 – April 26, 2026   4,173,143     $ 6.19       4,173,143     December 7, 2026   2,402,935     $ 2.11       (*)-     November 17, 2029   4,783,500     $ 0.85       4,783,500     October 2, 2029   15,308,085               12,898,150         (*) Exercisable from November 17, 2024.   d. Compensation Warrants     (i) A summary of changes in compensation warrants for the three-month period ended October 31, 2024 is presented below:       Number of warrants outstanding     Weighted average exercise price (*)   Balance, July 31, 2024     96,652       3.92   Granted in the September 2024 Offering     616,250       0.86   Granted in the October 2024 Offering     256,425       1.22   Balance, October 31, 2024     969,327     $ 1.26       (ii) As of October 31, 2024, compensation warrants outstanding were as follows:   Number of Warrants     Exercise Price     Exercisable At October 31, 2024     Expiry Date   4,890     $ 3.89       4,890     November 16, 2025   17,074     $ 5.31       17,074     February 26, 2026   24,688     $ 6.19       24,688     June 7, 2026   50,000     $ 2.32       (*)-   May 17, 2029   616,250     $ 0.86       (**)-   March 13, 2030   256,425     $ 1.22       256,425     October 2, 2029   969,327               303,077         (*) Exercisable from November 17, 2024. (**) Exercisable from March 11, 2025.     BriaCell Therapeutics Corp Notes to the Condensed Consolidated Financial Statements (Unaudited, expressed in US Dollars, except share and per share data and unless otherwise indicated)   NOTE 6: SHAREHOLDERS’ EQUITY (Cont.)   e. Warrant liability continuity   The following table presents the summary of the changes in the fair value of the warrants:       Warrants liability           Balance as of August 1, 2024   $ 1,096,036   Change in fair value during the period   $ 616,643             Balance as of October 31, 2024   $ 1,712,679     The key inputs used in the valuation of the non-public warrants as of October 31, 2024 and at July 31, 2024 were as follows:       October 31, 2024     July 31, 2024                 Share price   $ 0.81     $ 0.75   Exercise price   $ 5.31-6.19     $ 5.31-6.19   Expected life (years)     1.32-2.10     1.57-2.35   Volatility     93-106 %     77-79 % Dividend yield     0 %     0 % Risk free rate     4.19-4.29 %     4.27 %   The key inputs used in the valuation of the of the BriaPro Warrant Shares as of October 31, 2024 were as follows:       August 31, 2023 (Effective Date)     October 31, 2024                 Share price   $ 0.0365     $ 0.0365   Exercise price   $ 0.0206-0.0308   $ 0.0206-0.0308 Expected life (years)     2.21-3.27       1.05-2.10   Volatility     100 %     93-106 % Dividend yield     0 %     0 % Risk free rate     4.40 %     3.07 %

SHARE-BASED COMPENSATION	3 Months Ended
	Oct. 31, 2024
Share-Based Payment Arrangement [Abstract]
SHARE-BASED COMPENSATION	NOTE 7: SHARE-BASED COMPENSATION     a. On August 2, 2022, the Company approved an omnibus equity incentive plan (“Omnibus Plan), which will permit the Company to grant incentive stock options, preferred share units, restricted share units (“RSU’s”), and deferred share units (collectively, the “Awards”) for the benefit of any employee, officer, director, or consultant of the Company or any subsidiary of the Company. The maximum number of shares available for issuance under the Omnibus Plan shall not exceed 15% of the issued and outstanding Shares, from time to time, less the number of Shares reserved for issuance under all other security-based compensation arrangements of the Company, including the existing Stock Option Plan. On February 9, 2023, the Omnibus Plan was approved by the shareholders.     b. The following table summarizes the number of options granted to directors, officers, employees and consultants under the option plan for three-month period ended October 31, 2024 and related information:       Number of options     Weighted average exercise price     Weighted average remaining contractual term (in years)     Aggregate intrinsic value                             Balance as of July 31, 2024     2,131,400     $ 6.16       2.52     $           -                                     Balance as of October 31, 2024     2,131,400       6.15       2.27       -                                     Exercisable as of October 31, 2024     2,018,775     $ 6.16       2.20     $ -     As of October 31, 2024, there are $519,598 of total unrecognized costs related to share-based compensation that is expected to be recognized over a period of up to 6 months.     BriaCell Therapeutics Corp Notes to the Condensed Consolidated Financial Statements (Unaudited, expressed in US Dollars, except share and per share data and unless otherwise indicated)   NOTE 7: SHARE-BASED COMPENSATION (Cont.)   c. The following table summarizes information about the Company’s outstanding and exercisable options granted to employees as of October 31, 2024.   Exercise price     Options outstanding as of October 31, 2024     Weighted average remaining contractual term (years)     Options exercisable as of October 31, 2024     Weighted average remaining contractual term (years)     Expiry Date                                 $ 6.03       440,000       3.64       330,000       3.64     June 20, 2028 $ 7.16       21,000       3.33       18,375       3.33     February 27, 2028 $ 6.04       180,100       2.76       180,100       2.76     August 02, 2027 $ 4.71       31,000       2.56       31,000       2.56     May 20, 2027 $ 7.51       150,000       2.29       150,000       2.29     February 16, 2027 $ 8.47       524,700       2.20       524,700       2.20     January 13, 2027 $ 7.15       12,600       2.00       12,600       2.00     November 01, 2026 $ 5.74       100,000       1.84       100,000       1.84     September 01, 2026 $ 4.24       60,000       1.47       60,000       1.47     April 19, 2026 $ 4.24       612,000       1.41       612,000       1.41     March 29, 2026           2,131,400               2,018,775                   d. As result of the Arrangement, 2,131,400 BriaPro Options were issued and are outstanding as of October 31, 2024:   Exercise Price     Options outstanding as of October 31, 2024     Options exercisable as of October 31, 2024     Expiry Date                     $ 0.0933       440,000       330,000     June 20, 2028 $ 0.1108       21,000       18,375     February 27, 2028 $ 0.0984       180,100       180,100     August 02, 2027 $ 0.0729       31,000       31,000     May 20, 2027 $ 0.1162       150,000       150,000     February 16, 2027 $ 0.1310       524,700       524,700     January 13, 2027 $ 0.1165       12,600       12,600     November 01, 2026 $ 0.0888       100,000       100,000     September 01, 2026 $ 0.0656       60,000       60,000     April 19, 2026 $ 0.0656       612,000       612,000     March 29, 2026           2,131,400       2,018,775         e. Restricted Share Unit Plan   The following table summarizes the number of RSU’s granted to directors under the Omnibus plan as of October 31, 2024:       Number of RSU’s outstanding     Aggregate intrinsic value   Balance, July 31, 2024     19,200     $ 14,400   Balance, October 31, 2024     19,200     $ 15,552     f. The total share-based compensation expense related to all of the Company’s equity-based awards, recognized for the three-month period ended October 31, 2024 and 2023 is comprised as follows:       Three months ended October 31,       2024     2023                 Research and development expenses   $ 32,718       257,809   General and administrative expenses     234,253       276,007   Total share-based compensation   $ 266,971       533,816       BriaCell Therapeutics Corp Notes to the Condensed Consolidated Financial Statements (Unaudited, expressed in US Dollars, except share and per share data and unless otherwise indicated)

BASIC AND DILUTED NET LOSS PER SHARE	3 Months Ended
	Oct. 31, 2024
Earnings Per Share [Abstract]
BASIC AND DILUTED NET LOSS PER SHARE	NOTE 8: BASIC AND DILUTED NET LOSS PER SHARE   Basic net income (loss) per ordinary share is computed by dividing net income (loss) for each reporting period by the weighted-average number of ordinary shares outstanding during each year. Diluted net income (loss) per ordinary share is computed by dividing net income (loss) for each reporting period by the weighted average number of ordinary shares outstanding during the period, plus dilutive potential ordinary shares considered outstanding during the period, in accordance with ASC No. 260-10 “Earnings Per Share”. The company reported a loss for the three-month period ending October 31, 2023, leading to the exclusion of potentially dilutive ordinary shares. Conversely, a gain was recorded for the three-month period ending October 31, 2024, resulting in the inclusion of all potentially dilutive ordinary shares.       Three months ended October 31,       2024     2023       (Unaudited)     (Unaudited)   Basic EPS                 Numerator:                 Net income (loss)   $ (5,802,175 )   $ 6,001,543   Denominator:                 Shares used in computation of basic earnings per share     26,641,036       15,981,726   Basic EPS   $ (0.22 )   $ 0.38   Diluted EPS                 Numerator:                 Net income (loss) attributable to common stock, basic   $ (5,802,175 )   $ 6,001,543   Adjustment: Change in fair value of warrant liability     -       (14,282,078 ) Net (loss) attributable to common stock, diluted   $ (5,802,175 )   $ (8,280,535 ) Denominator:                 Shares used in computing net EPS of common stock, basic     26,641,036       15,981,726   Stock Options     -       211,434   Warrants     -       481,731   Shares used in computation of diluted earnings per share     26,641,036       16,674,891   Diluted EPS   $ (0.22 )   $ (0.50 )

FINANCIAL INCOME (EXPENSES), NET	3 Months Ended
	Oct. 31, 2024
Other Income and Expenses [Abstract]
FINANCIAL INCOME (EXPENSES), NET	NOTE 9: FINANCIAL INCOME (EXPENSES), NET       Three months ended October 31,       2024     2023   Interest income   $ 13,050     $ 190,815   Foreign exchange loss     (1,336 )     (10,993 ) Financial income, net   $ 11,714     $ 179,822

SUBSEQUENT EVENTS	3 Months Ended
	Oct. 31, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 10: SUBSEQUENT EVENTS   a. Between December 3, 2024 and December 10, 2024, a 620,900 October 2024 Warrants were exercised into 620,900 common shares of the Company, generating gross proceeds of $527,765.   b. On December 13, 2024, the Company closed a public offering for the purchase and sale of 7,400,000 common shares of the Company and warrants to purchase up to an aggregate of 7,400,000 common shares of the Company for aggregate gross proceeds of approximately $5.55 million before deducting underwriting discounts, commissions, and other offering expenses (the “December 2024 Offering”). Each common share was sold together with one warrant to purchase one common share at a combined purchase price of $0.75. The warrants have an exercise price of $0.9375 per share, and are immediately exercisable for a period of five years from the closing date. In addition, the Company issued 370,000 agent warrants. The agent warrants are immediately exercisable for a period of five years from the closing date at an exercise price of $0.9375.

SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Oct. 31, 2024
Accounting Policies [Abstract]
Use of estimates	a. Use of estimates:       The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company’s management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities at the dates of the condensed consolidated financial statements, and the reported amount of expenses during the reporting periods. Actual results could differ from those estimates.
Prepaid expenses	b. Prepaid expenses       The Company has prepaid certain expenses in respect of its pivotal phase III trial and estimates the period over which such expenses will be incurred. As of July 31, 2024, the Company revised its estimate of the time to completion in respect of this trial. Amounts estimated to be expenses in more than 12 months have been classified to long-term prepaid expenses.
The useful life of property and equipment	c. The useful life of property and equipment       Property and equipment are depreciated over their useful lives. Useful lives are based on management’s estimates of the period that the assets will be used which are periodically reviewed for continued appropriateness. Changes to estimates can result in significant variations in the amounts charged to the consolidated statement of operations and comprehensive loss in specific periods.
Investment equity method	d. Investment equity method:       Investments in entities over which the Company does not have a controlling financial interest but has significant influence are accounted for using the equity method, with the Company’s share of losses reported in the loss from equity method investments on the statements of operation and comprehensive loss. The Company has a 54.6% interest in BC Therapeutics. Management evaluates whether it has control over the investee in accordance with the guidance of ASC 810, which requires judgment to assess factors such as power over significant activities of the investee, exposure to variable returns, and the ability to affect those returns. Based on this evaluation, management determines whether control or significant influence is present for accounting purposes.
Recently issued and adopted accounting standards	e. Recently issued and adopted accounting standards:       As an “emerging growth company,” the Jumpstart Our Business Startups Act (“JOBS Act”) allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this extended transition period under the JOBS Act. The adoption dates discussed below reflect this election. The pronouncements below relate to standards that impact the Company.       1. In December 2023, the FASB issued ASU 2023-09 - Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This standard modifies the rules on income tax disclosures to require entities to disclose specific categories in the rate reconciliation, the income or loss from continuing operations before income tax expense or benefit, and income tax expense or benefit from continuing operations. ASU 2023-09 also requires entities to disclose their income tax payments to international, federal, state, and local jurisdictions. The ASU is effective for years beginning after December 15, 2024, but early adoption is permitted. This ASU should be applied on a prospective basis, although retrospective application is permitted. The Company is currently evaluating the impact of this standard on its financial statements and disclosures.         2. In March 2024, the FASB issued ASU 2024-01 - Compensation—Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar Awards. This standard clarifies whether profits interest and similar awards fall within the scope of stock-based compensation guidance as defined in ASC Topic 718, introducing examples to demonstrate this. The ASU includes scenarios where profits interest awards are classified as equity instruments or liability awards and situations where they fall outside ASC Topic 718, being accounted for under ASC Topic 710. The ASU is effective for years beginning after December 15, 2024, but early adoption is permitted. This ASU should be applied on a prospective basis, although retrospective application is permitted. The Company is currently evaluating the impact of this standard on its financial statements and disclosures.

INVESTMENT IN BC THERAPEUTICS INC. (Tables)	3 Months Ended
	Oct. 31, 2024
Investments, All Other Investments [Abstract]
SCHEDULE OF CHANGES IN INVESTMENT	Changes in the Company’s equity investment in BC Therapeutics is summarized as follows:   Balance – August 1, 2023   $ -   Funding (including the value of the BC Therapeutics Options)     525,000   Share of losses     (106,510 ) Balance – July 31, 2024     418,490   Funding     75,000   Share of losses     (71,515 ) Balance – October 31, 2024   $ 421,975
SCHEDULE OF ASSETS AND LIABILITIES OF BC THERAPEUTICS	The following amounts represent the Company’s 54.6% share of the assets of BC Therapeutics:        As of October 31, 2024   Current assets: Cash   $ 2,805   Net assets   $ 2,805

FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended
	Oct. 31, 2024
Fair Value Disclosures [Abstract]
SCHEDULE OF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE ON A RECURRING BASIS	The following table presents information about our financial instruments that are measured at fair value on a recurring basis as of October 31, 2024 and July 31, 2024:       Fair Value Measurements at       October 31, 2024     July 31, 2024       Level 1     Level 2     Total     Level 1     Level 2     Total   Financial Assets:                                                 Cash and cash equivalents     5,792,265       -       5,792,265       862,089       -       862,089                                                     Total assets measured at fair value   $ 5,792,265     $ -     $ 5,792,265     $ 862,809     $ -     $ 862,089                                                     Financial liabilities:                                                 Warrants liability     1,207,621       505,058       1,712,679       760,657       335,379       1,096,036                                                     Total liabilities measured at fair value   $ 1,207,621     $ 505,058     $ 1,712,679     $ 760,657     $ 335,379     $ 1,096,036

SHAREHOLDERS’ EQUITY (Tables)	3 Months Ended
	Oct. 31, 2024
Accumulated Other Comprehensive Income (Loss) [Line Items]
SCHEDULE OF CHANGE IN FAIR VALUE OF WARRANTS	The following table presents the summary of the changes in the fair value of the warrants:       Warrants liability           Balance as of August 1, 2024   $ 1,096,036   Change in fair value during the period   $ 616,643             Balance as of October 31, 2024   $ 1,712,679
SCHEDULE OF VALUATION OF NON-PUBLIC WARRANTS	The key inputs used in the valuation of the non-public warrants as of October 31, 2024 and at July 31, 2024 were as follows:       October 31, 2024     July 31, 2024                 Share price   $ 0.81     $ 0.75   Exercise price   $ 5.31-6.19     $ 5.31-6.19   Expected life (years)     1.32-2.10     1.57-2.35   Volatility     93-106 %     77-79 % Dividend yield     0 %     0 % Risk free rate     4.19-4.29 %     4.27 %
SCHEDULE OF BRIA PRO WARRANTS	The key inputs used in the valuation of the of the BriaPro Warrant Shares as of October 31, 2024 were as follows:       August 31, 2023 (Effective Date)     October 31, 2024                 Share price   $ 0.0365     $ 0.0365   Exercise price   $ 0.0206-0.0308   $ 0.0206-0.0308 Expected life (years)     2.21-3.27       1.05-2.10   Volatility     100 %     93-106 % Dividend yield     0 %     0 % Risk free rate     4.40 %     3.07 %
Share Purchase Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
SUMMARY OF CHANGES IN WARRANTS	A summary of changes in share purchase warrants for the three-month period ending October 31, 2024 is presented below:       Number of options outstanding     Weighted average exercise price (*)   Balance, July 31, 2024     10,524,585     $ 4.92   Exercised     (345,000 )     (0.85 ) Granted in the October 2024 Offering     5,128,500       0.85   Balance, October 31, 2024     15,308,085     $ 3.65
SCHEDULE OF WARRANTS OUTSTANDING	Number of Warrants     Exercise Price(*)     Exercisable At October 31, 2024     Expiry Date   51,698     $ 3.89       51,698     November 16, 2025   3,896,809     $ 5.31       3,896,809     February 26, 2026 – April 26, 2026   4,173,143     $ 6.19       4,173,143     December 7, 2026   2,402,935     $ 2.11       (*)-     November 17, 2029   4,783,500     $ 0.85       4,783,500     October 2, 2029   15,308,085               12,898,150         (*) Exercisable from November 17, 2024.
Compensation Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
SUMMARY OF CHANGES IN WARRANTS	Number of warrants outstanding     Weighted average exercise price (*)   Balance, July 31, 2024     96,652       3.92   Granted in the September 2024 Offering     616,250       0.86   Granted in the October 2024 Offering     256,425       1.22   Balance, October 31, 2024     969,327     $ 1.26
SCHEDULE OF WARRANTS OUTSTANDING	Number of Warrants     Exercise Price     Exercisable At October 31, 2024     Expiry Date   4,890     $ 3.89       4,890     November 16, 2025   17,074     $ 5.31       17,074     February 26, 2026   24,688     $ 6.19       24,688     June 7, 2026   50,000     $ 2.32       (*)-   May 17, 2029   616,250     $ 0.86       (**)-   March 13, 2030   256,425     $ 1.22       256,425     October 2, 2029   969,327               303,077         (*) Exercisable from November 17, 2024. (**) Exercisable from March 11, 2025.

SHARE-BASED COMPENSATION (Tables)	3 Months Ended
	Oct. 31, 2024
Defined Benefit Plan Disclosure [Line Items]
SUMMARY OF NUMBER OF OPTIONS GRANTED	Number of options     Weighted average exercise price     Weighted average remaining contractual term (in years)     Aggregate intrinsic value                             Balance as of July 31, 2024     2,131,400     $ 6.16       2.52     $           -                                     Balance as of October 31, 2024     2,131,400       6.15       2.27       -                                     Exercisable as of October 31, 2024     2,018,775     $ 6.16       2.20     $ -
SUMMARY OF OUTSTANDING AND EXERCISABLE OPTIONS	Exercise price     Options outstanding as of October 31, 2024     Weighted average remaining contractual term (years)     Options exercisable as of October 31, 2024     Weighted average remaining contractual term (years)     Expiry Date                                 $ 6.03       440,000       3.64       330,000       3.64     June 20, 2028 $ 7.16       21,000       3.33       18,375       3.33     February 27, 2028 $ 6.04       180,100       2.76       180,100       2.76     August 02, 2027 $ 4.71       31,000       2.56       31,000       2.56     May 20, 2027 $ 7.51       150,000       2.29       150,000       2.29     February 16, 2027 $ 8.47       524,700       2.20       524,700       2.20     January 13, 2027 $ 7.15       12,600       2.00       12,600       2.00     November 01, 2026 $ 5.74       100,000       1.84       100,000       1.84     September 01, 2026 $ 4.24       60,000       1.47       60,000       1.47     April 19, 2026 $ 4.24       612,000       1.41       612,000       1.41     March 29, 2026           2,131,400               2,018,775
SCHEDULE OF RESTRICTED STOCK UNITS GRANTED	The following table summarizes the number of RSU’s granted to directors under the Omnibus plan as of October 31, 2024:       Number of RSU’s outstanding     Aggregate intrinsic value   Balance, July 31, 2024     19,200     $ 14,400   Balance, October 31, 2024     19,200     $ 15,552
SCHEDULE OF SHARE-BASED COMPENSATION EXPENSES	Three months ended October 31,       2024     2023                 Research and development expenses   $ 32,718       257,809   General and administrative expenses     234,253       276,007   Total share-based compensation   $ 266,971       533,816
Bria Pro Therapeutics Corp [Member]
Defined Benefit Plan Disclosure [Line Items]
SUMMARY OF OUTSTANDING AND EXERCISABLE OPTIONS	Exercise Price     Options outstanding as of October 31, 2024     Options exercisable as of October 31, 2024     Expiry Date                     $ 0.0933       440,000       330,000     June 20, 2028 $ 0.1108       21,000       18,375     February 27, 2028 $ 0.0984       180,100       180,100     August 02, 2027 $ 0.0729       31,000       31,000     May 20, 2027 $ 0.1162       150,000       150,000     February 16, 2027 $ 0.1310       524,700       524,700     January 13, 2027 $ 0.1165       12,600       12,600     November 01, 2026 $ 0.0888       100,000       100,000     September 01, 2026 $ 0.0656       60,000       60,000     April 19, 2026 $ 0.0656       612,000       612,000     March 29, 2026           2,131,400       2,018,775

BASIC AND DILUTED NET LOSS PER SHARE (Tables)	3 Months Ended
	Oct. 31, 2024
Earnings Per Share [Abstract]
SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE	Three months ended October 31,       2024     2023       (Unaudited)     (Unaudited)   Basic EPS                 Numerator:                 Net income (loss)   $ (5,802,175 )   $ 6,001,543   Denominator:                 Shares used in computation of basic earnings per share     26,641,036       15,981,726   Basic EPS   $ (0.22 )   $ 0.38   Diluted EPS                 Numerator:                 Net income (loss) attributable to common stock, basic   $ (5,802,175 )   $ 6,001,543   Adjustment: Change in fair value of warrant liability     -       (14,282,078 ) Net (loss) attributable to common stock, diluted   $ (5,802,175 )   $ (8,280,535 ) Denominator:                 Shares used in computing net EPS of common stock, basic     26,641,036       15,981,726   Stock Options     -       211,434   Warrants     -       481,731   Shares used in computation of diluted earnings per share     26,641,036       16,674,891   Diluted EPS   $ (0.22 )   $ (0.50 )

FINANCIAL INCOME (EXPENSES), NET (Tables)	3 Months Ended
	Oct. 31, 2024
Other Income and Expenses [Abstract]
SCHEDULE OF FINANCIAL INCOME (EXPENSES), NET	Three months ended October 31,       2024     2023   Interest income   $ 13,050     $ 190,815   Foreign exchange loss     (1,336 )     (10,993 ) Financial income, net   $ 11,714     $ 179,822

GENERAL AND GOING CONCERN (Details Narrative) - USD ($)		1 Months Ended		3 Months Ended
	Aug. 31, 2023	Oct. 31, 2024	Sep. 30, 2024	Oct. 31, 2024	Oct. 31, 2023	Jul. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accumulated deficit		$ 91,245,872		$ 91,245,872		$ 85,443,697
Cash flows from operating activities				6,955,076	$ 7,605,245
Aggregate gross proceeds		$ 5,000,000.0	$ 8,500,000	$ 11,667,001
Common stock, shares issued		36,183,161		36,183,161		18,284,661
Common stock, shares outstanding		36,183,161		36,183,161		18,284,661
Services Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Monthly fees	$ 20,000
Bria Pro Therapeutics Corp [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of shares issued and outstanding		66.60%		66.60%
Common stock, shares issued		47,945,178		47,945,178
Common stock, shares outstanding		47,945,178		47,945,178
Common shares owned		31,963,452		31,963,452

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	Oct. 31, 2024
BC Therapeutics [Member]
Investment equity method percentage	54.60%

SCHEDULE OF CHANGES IN INVESTMENT (Details) - USD ($)	3 Months Ended		12 Months Ended
	Oct. 31, 2024	Oct. 31, 2023	Jul. 31, 2024
Restructuring Cost and Reserve [Line Items]
Funding	$ 75,000
Share of losses	(71,515)
BC Therapeutics [Member]
Restructuring Cost and Reserve [Line Items]
Beginning balance	418,490
Funding	75,000		525,000
Share of losses	(71,515)		(106,510)
Ending balance	$ 421,975		$ 418,490

SCHEDULE OF ASSETS AND LIABILITIES OF BC THERAPEUTICS (Details) - BC Therapeutics [Member]	Oct. 31, 2024 USD ($)
Restructuring Cost and Reserve [Line Items]
Current assets: Cash	$ 2,805
Net assets	$ 2,805

INVESTMENT IN BC THERAPEUTICS INC. (Details Narrative) - USD ($)			3 Months Ended		12 Months Ended
	Aug. 07, 2024	Dec. 21, 2021	Oct. 31, 2024	Oct. 31, 2023	Jul. 31, 2024	Feb. 01, 2024
Payment for equity investments			$ 75,000
Share price			$ 0.81		$ 0.75
Dividend yield			0.00%		0.00%
Risk free interest rate					4.27%
Options exercised			60,000
Options exercised, value			$ 75,000
BC Therapeutics [Member]
Payment for equity investments			$ 75,000		$ 525,000
Number of shares issued			480,000
Percent of issued and outstanding shares			54.60%
Share Purchase Agreement [Member]
Share price		$ 1.25
Fair value, option		$ 76,350
Exercise price		$ 1.25
Dividend yield		0.00%
Risk free interest rate		4.902%
Volatility		100.00%
Share Purchase Agreement [Member] | BC Therapeutics [Member]
Assets and liabilities owned percentage			54.60%
Share Purchase Agreement [Member] | BC Therapeutics [Member] | Two Options [Member]
Payment for equity investments		$ 225,000
Share price		$ 1.25
Share Purchase Agreement [Member] | BC Therapeutics [Member]
Payment for equity investments		$ 300,000
Share price		$ 1.25
Equity interest percentage		37.50%
Share Purchase Agreement [Member] | BC Therapeutics [Member] | First BC Therapeutics Option [Member]
Equity interest percentage						51.20%
Share Purchase Agreement [Member] | BC Therapeutics [Member] | Second BC Therapeutics Option [Member]
Share price	$ 1.25
Options exercised	20,000

CONTINGENT LIABILITIES AND COMMITMENTS (Details Narrative)	3 Months Ended
	Oct. 31, 2024 USD ($)
Office and Lab Space [Member]
Loss Contingencies [Line Items]
Lease term	12 months
Operating lease payments	$ 38,110
Lease expiration date	Aug. 31, 2024
Bria Pro Therapeutics Corp [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Warrant exercise amount payable	$ 241,164

SCHEDULE OF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE ON A RECURRING BASIS (Details) - USD ($)	Oct. 31, 2024	Jul. 31, 2024
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value	$ 5,792,265	$ 862,089
Total liabilities measured at fair value	1,712,679	1,096,036
Warrants Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities measured at fair value	1,712,679	1,096,036
Cash and Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value	5,792,265	862,089
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value	5,792,265	862,809
Total liabilities measured at fair value	1,207,621	760,657
Fair Value, Inputs, Level 1 [Member] | Warrants Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities measured at fair value	1,207,621	760,657
Fair Value, Inputs, Level 1 [Member] | Cash and Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value	5,792,265	862,089
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value
Total liabilities measured at fair value	505,058	335,379
Fair Value, Inputs, Level 2 [Member] | Warrants Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities measured at fair value	505,058	335,379
Fair Value, Inputs, Level 2 [Member] | Cash and Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value

SUMMARY OF CHANGES IN WARRANTS (Details)	3 Months Ended
	Oct. 31, 2024 $ / shares shares
Share Purchase Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants outstanding, beginning balance | shares	10,524,585
Weighted average exercise price, beginning balance	$ 4.92
Number of warrants outstanding, exercised | shares	(345,000)
Weighted average exercise price, exercised	$ (0.85)
Granted in a registered direct offering | shares	5,128,500
Weighted average exercise price, Granted in a registered direct offering	$ 0.85
Number of warrants outstanding, ending balance | shares	15,308,085
Weighted average exercise price, Ending balance	$ 3.65
Weighted average exercise price, Granted in a registered direct offering	$ (0.85)
Compensation Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants outstanding, beginning balance | shares	96,652
Weighted average exercise price, beginning balance	$ 3.92
Granted in a registered direct offering | shares	616,250
Weighted average exercise price, Granted in a registered direct offering	$ (0.86)
Number of warrants outstanding, ending balance | shares	969,327
Weighted average exercise price, Ending balance	$ 1.26
Weighted average exercise price, Granted in a registered direct offering	$ 0.86
Compensation Warrants One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Granted in a registered direct offering | shares	256,425
Weighted average exercise price, Granted in a registered direct offering	$ (1.22)
Weighted average exercise price, Granted in a registered direct offering	$ 1.22

SCHEDULE OF WARRANTS OUTSTANDING (Details)	3 Months Ended
	Oct. 31, 2024 $ / shares shares
Share Purchase Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants outstanding	15,308,085
Number of warrants exercisable	12,898,150
Share Purchase Warrants [Member] | Warrant One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants outstanding	51,698
Exercise price | $ / shares	$ 3.89	[1]
Number of warrants exercisable	51,698
Expiry date	Nov. 16, 2025
Share Purchase Warrants [Member] | Warrant Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants outstanding	3,896,809
Exercise price | $ / shares	$ 5.31	[1]
Number of warrants exercisable	3,896,809
Share Purchase Warrants [Member] | Warrant Two [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expiry date	Feb. 26, 2026
Share Purchase Warrants [Member] | Warrant Two [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expiry date	Apr. 26, 2026
Share Purchase Warrants [Member] | Warrant Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants outstanding	4,173,143
Exercise price | $ / shares	$ 6.19	[1]
Number of warrants exercisable	4,173,143
Expiry date	Dec. 07, 2026
Share Purchase Warrants [Member] | Warrant Four [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants outstanding	2,402,935
Exercise price | $ / shares	$ 2.11	[1]
Number of warrants exercisable		[1]
Expiry date	Nov. 17, 2029
Share Purchase Warrants [Member] | Warrant Five [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants outstanding	4,783,500
Exercise price | $ / shares	$ 0.85	[1]
Number of warrants exercisable	4,783,500
Expiry date	Oct. 02, 2029
Compensation Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants outstanding	969,327
Number of warrants exercisable	303,077
Compensation Warrants [Member] | Warrant One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants outstanding	4,890
Exercise price | $ / shares	$ 3.89
Number of warrants exercisable	4,890
Expiry date	Nov. 16, 2025
Compensation Warrants [Member] | Warrant Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants outstanding	17,074
Exercise price | $ / shares	$ 5.31
Number of warrants exercisable	17,074
Expiry date	Feb. 26, 2026
Compensation Warrants [Member] | Warrant Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants outstanding	24,688
Exercise price | $ / shares	$ 6.19
Number of warrants exercisable	24,688
Expiry date	Jun. 07, 2026
Compensation Warrants [Member] | Warrant Four [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants outstanding	50,000
Exercise price | $ / shares	$ 2.32
Number of warrants exercisable		[2]
Expiry date	May 17, 2029
Compensation Warrants [Member] | Warrant Five [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants outstanding	616,250
Exercise price | $ / shares	$ 0.86
Number of warrants exercisable		[3]
Expiry date	Mar. 13, 2030
Compensation Warrants [Member] | Warrant Six [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants outstanding	256,425
Exercise price | $ / shares	$ 1.22
Number of warrants exercisable	256,425
Expiry date	Oct. 02, 2029
[1] Exercisable from November 17, 2024. [2] Exercisable from November 17, 2024. [3] Exercisable from March 11, 2025.

SCHEDULE OF CHANGE IN FAIR VALUE OF WARRANTS (Details) - Warrant [Member]	3 Months Ended
	Oct. 31, 2024 USD ($)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant liability, beginning balance	$ 1,096,036
Change in fair value during the period	616,643
Warrant liability, ending balance	$ 1,712,679

SCHEDULE OF VALUATION OF NON-PUBLIC WARRANTS (Details) - $ / shares	3 Months Ended	12 Months Ended
	Oct. 31, 2024	Jul. 31, 2024
Share price	$ 0.81	$ 0.75
Dividend yield	0.00%	0.00%
Risk free rate		4.27%
Minimum [Member]
Exercise price	$ 5.31	$ 5.31
Expected life	1 year 3 months 25 days	1 year 6 months 25 days
Volatility	93.00%	77.00%
Risk free rate	4.19%
Maximum [Member]
Exercise price	$ 6.19	$ 6.19
Expected life	2 years 1 month 6 days	2 years 4 months 6 days
Volatility	106.00%	79.00%
Risk free rate	4.29%

SCHEDULE OF BRIA PRO WARRANTS (Details) - $ / shares		3 Months Ended	12 Months Ended
	Aug. 31, 2023	Oct. 31, 2024	Jul. 31, 2024
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Share price		$ 0.81	$ 0.75
Dividend yield		0.00%	0.00%
Risk free rate			4.27%
Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Exercise price		$ 5.31	$ 5.31
Expected life (years)		1 year 3 months 25 days	1 year 6 months 25 days
Volatility		93.00%	77.00%
Risk free rate		4.19%
Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Exercise price		$ 6.19	$ 6.19
Expected life (years)		2 years 1 month 6 days	2 years 4 months 6 days
Volatility		106.00%	79.00%
Risk free rate		4.29%
Bria Pro Warrant [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Share price	$ 0.0365	$ 0.0365
Dividend yield	0.00%	0.00%
Risk free rate	4.40%	3.07%
Bria Pro Warrant [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Exercise price	$ 0.0206	$ 0.0206
Expected life (years)	2 years 2 months 15 days	1 year 18 days
Volatility		93.00%
Bria Pro Warrant [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Exercise price	$ 0.0308	$ 0.0308
Expected life (years)	3 years 3 months 7 days	2 years 1 month 6 days
Volatility	100.00%	106.00%

SHAREHOLDERS’ EQUITY (Details Narrative)				1 Months Ended	3 Months Ended		12 Months Ended
	Oct. 02, 2024 USD ($) $ / shares shares	Sep. 12, 2024 USD ($) $ / shares shares	May 17, 2024 shares	Oct. 31, 2024 USD ($) $ / shares shares	Oct. 31, 2024 USD ($) $ / shares	Oct. 31, 2023 USD ($)	Jul. 31, 2024 $ / shares
Subsidiary, Sale of Stock [Line Items]
Common stock, shares authorized					Unlimited		Unlimited
Common stock, no par value				$ 0	$ 0		$ 0
Warrant offering price				0.81	$ 0.81		$ 0.75
Gross proceeds from common shares | $					$ 11,667,001
Fair value adjustment of warrants | $					$ 616,643	$ (14,282,078)
Placement Agent Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Number of warrant shares | shares	256,425
Warrants outstanding, measurement input	1.01
Fair value adjustment of warrants | $	$ 204,128
October 2024 Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant offering price				$ 0.85	$ 0.85
Number of warrant shares | shares	5,128,500
Fair value adjustment of warrants | $	$ 2,211,266
Measurement Input, Share Price [Member] | Broker Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding, measurement input		0.63
Measurement Input, Share Price [Member] | October 2024 Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding, measurement input	0.54
Measurement Input, Exercise Price [Member] | Broker Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding, measurement input		0.8625
Measurement Input, Exercise Price [Member] | Placement Agent Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding, measurement input	1.22
Measurement Input, Exercise Price [Member] | October 2024 Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding, measurement input	0.85
Measurement Input, Expected Term [Member] | Broker Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants expected life		5 years
Measurement Input, Expected Term [Member] | Placement Agent Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants expected life	5 years
Measurement Input, Expected Term [Member] | October 2024 Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants expected life	5 years
Measurement Input, Price Volatility [Member] | Broker Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding, measurement input		109
Measurement Input, Price Volatility [Member] | Placement Agent Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding, measurement input	112
Measurement Input, Price Volatility [Member] | October 2024 Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding, measurement input	121
Measurement Input, Expected Dividend Rate [Member] | Broker Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding, measurement input		0
Measurement Input, Expected Dividend Rate [Member] | Placement Agent Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding, measurement input	0
Measurement Input, Expected Dividend Rate [Member] | October 2024 Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding, measurement input	0
Measurement Input, Risk Free Interest Rate [Member] | Broker Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding, measurement input		3.469
Measurement Input, Risk Free Interest Rate [Member] | Placement Agent Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding, measurement input	3.561
Measurement Input, Risk Free Interest Rate [Member] | October 2024 Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding, measurement input	3.553
Measurement Input Non Marketability Discount [Member] | Broker Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding, measurement input		16.38
September 2024 Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued | shares		12,325,000
Warrant offering price		$ 0.69
Gross proceeds from common shares | $		$ 8,500,000
Number of warrant shares | shares		616,250
Exercise price		$ 0.8625
Warrants expected life		5 years
October 2024 Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued | shares	5,128,500		5,128,500
Number of warrant shares | shares	256,425
Exercise price	$ 0.85
Warrants expected life	5 years
Gross proceeds from warrant | $	$ 5,000,000
October 2024 Offering [Member] | Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Exercise price	$ 0.975
October 2024 Offering [Member] | Placement Agent Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Exercise price	$ 1.21875
October 2024 Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued | shares				345,000
Gross proceeds from warrant | $				$ 293,250

SUMMARY OF NUMBER OF OPTIONS GRANTED (Details) - Stock Option Plan [Member] - USD ($)	3 Months Ended	12 Months Ended
	Oct. 31, 2024	Jul. 31, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options, beginning balance	2,131,400
Weighted average exercise price, beginning balance	$ 6.16
Weighted average remaining contractual term (in years)	2 years 3 months 7 days	2 years 6 months 7 days
Aggregate intrinsic value, beginning balance
Number of options, ending balance	2,131,400	2,131,400
Weighted average exercise price, ending balance	$ 6.15	$ 6.16
Aggregate intrinsic value, ending balance
Number of options, exercisable	2,018,775
Weighted average exercise price, exercisable	$ 6.16
Weighted average remaining contractual term (in years), exercisable	2 years 2 months 12 days
Aggregate intrinsic value, exercisable

SCHEDULE OF NUMBER OF OPTIONS GRANTED (Parenthetical) (Details) - Stock Option Plan [Member]	3 Months Ended
	Oct. 31, 2024 USD ($)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized costs	$ 519,598
Expected period	6 months

SCHEDULE OF OUTSTANDING AND EXERCISABLE OPTIONS (Details)	3 Months Ended
	Oct. 31, 2024 $ / shares shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding	2,131,400
Options exercisable	2,018,775
Exercise Price 6.03 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 6.03
Options outstanding	440,000
Weighted average remaining contractual term (years)	3 years 7 months 20 days
Options exercisable	330,000
Expiry Date	Jun. 20, 2028
Exercise Price 7.16 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 7.16
Options outstanding	21,000
Weighted average remaining contractual term (years)	3 years 3 months 29 days
Options exercisable	18,375
Expiry Date	Feb. 27, 2028
Exercise Price 6.04 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 6.04
Options outstanding	180,100
Weighted average remaining contractual term (years)	2 years 9 months 3 days
Options exercisable	180,100
Expiry Date	Aug. 02, 2027
Exercise Price 4.71 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 4.71
Options outstanding	31,000
Weighted average remaining contractual term (years)	2 years 6 months 21 days
Options exercisable	31,000
Expiry Date	May 20, 2027
Exercise Price 7.51 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 7.51
Options outstanding	150,000
Weighted average remaining contractual term (years)	2 years 3 months 14 days
Options exercisable	150,000
Expiry Date	Feb. 16, 2027
Exercise Price 8.47 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 8.47
Options outstanding	524,700
Weighted average remaining contractual term (years)	2 years 2 months 12 days
Options exercisable	524,700
Expiry Date	Jan. 13, 2027
Exercise Price 7.15 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 7.15
Options outstanding	12,600
Weighted average remaining contractual term (years)	2 years
Options exercisable	12,600
Expiry Date	Nov. 01, 2026
Exercise Price 5.74 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 5.74
Options outstanding	100,000
Weighted average remaining contractual term (years)	1 year 10 months 2 days
Options exercisable	100,000
Expiry Date	Sep. 01, 2026
Exercise Price 4.24 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 4.24
Options outstanding	60,000
Weighted average remaining contractual term (years)	1 year 5 months 19 days
Options exercisable	60,000
Expiry Date	Apr. 19, 2026
Exercise Price 4.24 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 4.24
Options outstanding	612,000
Weighted average remaining contractual term (years)	1 year 4 months 28 days
Options exercisable	612,000
Expiry Date	Mar. 29, 2026

SUMMARY OF OUTSTANDING AND EXERCISABLE OPTIONS (Details)	3 Months Ended
	Oct. 31, 2024 $ / shares shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding	2,131,400
Options exercisable	2,018,775
Exercise Price 0.0933 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 0.0933
Options outstanding	440,000
Options exercisable	330,000
Expiry date	Jun. 20, 2028
Exercise Price 0.1108 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 0.1108
Options outstanding	21,000
Options exercisable	18,375
Expiry date	Feb. 27, 2028
Exercise Price 0.0984 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 0.0984
Options outstanding	180,100
Options exercisable	180,100
Expiry date	Aug. 02, 2027
Exercise Price 0.0729 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 0.0729
Options outstanding	31,000
Options exercisable	31,000
Expiry date	May 20, 2027
Exercise Price 0.1162 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 0.1162
Options outstanding	150,000
Options exercisable	150,000
Expiry date	Feb. 16, 2027
Exercise Price 0.1310 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 0.1310
Options outstanding	524,700
Options exercisable	524,700
Expiry date	Jan. 13, 2027
Exercise Price 0.1165 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 0.1165
Options outstanding	12,600
Options exercisable	12,600
Expiry date	Nov. 01, 2026
Exercise Price 0.0888 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 0.0888
Options outstanding	100,000
Options exercisable	100,000
Expiry date	Sep. 01, 2026
Exercise Price 0.0656 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 0.0656
Options outstanding	60,000
Options exercisable	60,000
Expiry date	Apr. 19, 2026
Exercise Price 0.0656 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 0.0656
Options outstanding	612,000
Options exercisable	612,000
Expiry date	Mar. 29, 2026

SCHEDULE OF RESTRICTED STOCK UNITS GRANTED (Details) - Restricted Stock Units (RSUs) [Member]	Oct. 31, 2024 USD ($) shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of RSU's outstanding, Beginning balance | shares	19,200
Aggregate intrinsic value, beginning balance | $	$ 14,400
Number of RSU's outstanding, Ending balance | shares	19,200
Aggregate intrinsic value, ending balance | $	$ 15,552

SCHEDULE OF SHARE-BASED COMPENSATION EXPENSES (Details) - USD ($)	3 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share-based compensation	$ 266,971	$ 533,816
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share-based compensation	32,718	257,809
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share-based compensation	$ 234,253	$ 276,007

SHARE-BASED COMPENSATION (Details Narrative) - shares	Aug. 02, 2022	Oct. 31, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options issued and outstanding		2,131,400
Stock Option Plan [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Acquiring percentage of issued and outstanding of common stock	15.00%

SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE (Details) - USD ($)	3 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Earnings Per Share [Abstract]
Net income (loss)	$ (5,802,175)	$ 6,001,543
Shares used in computing net EPS of common stock, basic	26,641,036	15,981,726
Basic EPS	$ (0.22)	$ 0.38
Net income (loss) attributable to common stock, basic	$ (5,802,175)	$ 6,001,543
Adjustment: Change in fair value of warrant liability		(14,282,078)
Net (loss) attributable to common stock, diluted	$ (5,802,175)	$ (8,280,535)
Stock Options		211,434
Warrants		481,731
Shares used in computation of diluted earnings per share	26,641,036	16,674,891
Diluted EPS	$ (0.22)	$ (0.50)

SCHEDULE OF FINANCIAL INCOME (EXPENSES), NET (Details) - USD ($)	3 Months Ended
	Oct. 31, 2024	Oct. 31, 2023
Other Income and Expenses [Abstract]
Interest income	$ 13,050	$ 190,815
Foreign exchange loss	(1,336)	(10,993)
Financial income, net	$ 11,714	$ 179,822

SUBSEQUENT EVENTS (Details Narrative) - USD ($)			3 Months Ended
	Dec. 13, 2024	Dec. 10, 2024	Oct. 31, 2024	Oct. 31, 2023
Subsequent Event [Line Items]
Proceeds from issuance of common stock			$ 11,667,001
Gross proceeds from warrant exercises			$ 293,251
Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from warrant exercises share		620,900
Proceeds from issuance of common stock		$ 620,900
Gross proceeds from warrant exercises		$ 527,765
Subsequent Event [Member] | IPO [Member]
Subsequent Event [Line Items]
Number of shares issued	7,400,000
Number of securities called by warrants or rights	7,400,000
Gross proceeds	$ 5,550,000
Description of warrant or rights	Each common share was sold together with one warrant to purchase one common share
Sale of stock, price per share	$ 0.75
Exercise price of warrants	$ 0.9375
Exercisable warrants term	5 years
Subsequent Event [Member] | IPO [Member] | Agent Warrants [Member]
Subsequent Event [Line Items]
Number of securities called by warrants or rights	370,000
Exercise price of warrants	$ 0.9375
Exercisable warrants term	5 years

---